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Inflammation is an integral part of the body defense mechanism that occurs in 
vascularized tissue in response to harmful stimuli that is perceived as being a threat to 
tissue homeostasis.  It is a complex physiological host response that is designed to 
neutralize and eliminate harmful agents, initiate tissue healing, and orchestrate a return to 
tissue homeostasis.  While inflammation is designed to be an acute event that resolves 
following the elimination of harmful stimuli and tissue healing, there are instances where 
inflammation fails to resolve and instead evolves into chronic inflammation.  It is now 
well understood that ongoing inflammation can serve as the underlying cause of many 
chronic inflammatory diseases, including atherosclerosis.  In fact, one of the most 
pressing issues that is currently faced in the field of inflammation research, one that has 
also become the focus of numerous ongoing investigations, is how to turn this excessive, 
unwarranted and undesirable inflammation response off. 
Once thought to be a passive and simple process, resolution is now understood to 
be an active and complex process that is orchestrated by various inflammatory mediators, 
signaling pathways and biophysical processes.  The discovery of novel biosynthetic 
pathways that turn on the pro-resolution signals has lead to a surge in research aimed at 
taking a closer look at processes that can stimulate the resolution of inflammation.  While 
major advances in the field have resulted in a better understanding of the proactive nature 
of resolution, many of the mechanisms involved are still unknown.   To date, the 
repertoire of chemokine receptors that participate in macrophage clearance during 
resolution, for the most part, remain unidentified.  Overall, there is a growing 
 xxi 
appreciation that the discovery of mechanisms involved in the resolution responses can 
lead to the development of novel therapeutic approaches to resolve many chronic 
inflammatory diseases.    
Syndecan-1 (Sdc-1), a member of a family of cell surface proteoglycans, has been 
previously shown to regulate events relevant to tissue repair and chronic injury responses.  
Sdc-1 expression during inflammation has been reported to be protective in various 
models, and in agreement with these published reports, our research group has recently 
demonstrated the protective nature of macrophages expressing Sdc-1 in the pathogenesis 
of abdominal aortic aneurysm.  Given these observations, we hypothesize that Sdc-1 
expression on macrophages is a critical component of an anti-inflammatory, pro 
resolution program necessary for the successful resolution of inflammatory response.   
In this dissertation, we report the presence of a unique population of macrophages 
expressing Sdc-1 that are present within the vascular wall of mice undergoing 
atherosclerosis.  Consistent with previous publications, the presence of Sdc-1 expressing 
macrophages was found to limit atherosclerosis progression.  In addition, Sdc-1 
expression on macrophages was associated with anti-inflammatory M2 polarization state 
and high intrinsic motility.  Macrophage Sdc-1 expression was also linked with 
efferocytosis and enhanced macrophage egress from the site of inflammation to the 
draining lymphatic network.  Moreover, we discovered that the chemokine receptor 
CXCR4, which was found on Sdc-1 expressing macrophages, was also involved in 
macrophage egress during inflammation resolution.  
 Following a brief overview of the overall research in Chapter 1, an attempt to 
provide a summary of current knowledge in the regulation of both acute and chronic 
 xxii 
inflammation, biophysical processes involving macrophages that are believed to be 
important in the resolution of inflammation, and how macrophage Sdc-1 expression can 
potentially affect inflammation outcome and help stimulate resolution, was included in 
Chapter 2.   
 In Chapter 3, we described our initial efforts to characterize the polarization state 
of macrophages expressing Sdc-1.  The expressions of surface markers that are known to 
be expressed on polarized macrophages were investigated.  Additional biochemical and 
biophysical functions of macrophages, including the intrinsic motility of polarized and 
Sdc-1 expressing macrophages were investigated.  These characterization efforts 
established the anti-inflammatory nature of Sdc-1 expressing macrophages, which was 
linked with increased macrophage migration response.  Importantly, we demonstrated 
efferocytosis to be a possible regulator of macrophage Sdc-1 expression.   
 The correlation that we discovered between efferocytosis, Sdc-1 expression and 
enhanced intrinsic motility motivated us to investigate the effects of macrophage Sdc-1 





 mice and a murine peritonitis model to investigate the effect of Sdc-1 expression 
on macrophage response and egress during inflammation.  Importantly, the absence of 
Sdc-1 was found to result in the accumulation of macrophages in the peritoneal cavity, 
which was associated with delayed macrophage clearance.  In addition, delayed 
macrophage clearance was found to be associated with dampened macrophage egress 
toward the draining lymph nodes.    
In Chapter 5, we discussed our efforts to identify specific chemokine receptor that 
is involved in macrophage egress during the resolution of inflammation.  While we 
 xxiii 
identified 3 chemokine receptors that were upregulated in Sdc-1 expressing M2 polarized 
macrophages, CX3CR1, CXCR4 and CCR10, only CXCR4 was found to be expressed 
and to be functionally active following macrophage efferocytosis.  Further tests utilizing 
AMD3100, a CXCR4 blocker, in murine peritonitis model confirmed that macrophage 
CXCR4 is involved in the regulation of macrophage response.  We demonstrated that 
CXCR4 blockade resulted in the accumulation of macrophages within the peritoneal 
cavity, which was associated with delayed macrophage egress toward the draining lymph 
nodes.  Overall, we were able to demonstrate that correlation between macrophage Sdc-1 
and macrophage CXCR4 expression, and their involvement in macrophage egress toward 













1.1       Significance 
Inflammation is a complex physiological host response that occurs in vascularized 
tissue in response to harmful stimuli that is perceived as being a threat to tissue 
homeostasis.  It is an integral part of the body defense mechanism that is designed to 
neutralize and eliminate harmful agents, initiate tissue repairs, and direct a return to tissue 
homeostasis.  While inflammation is designed to be an acute event that resolves once the 
harmful stimuli are eliminated, there are cases where inflammation fails to resolve.  In 
fact, it is now understood that chronic inflammation can contribute to the pathogenesis of 
many diseases, including rheumatoid arthritis, autoimmune disorders, aneurysm, and 
atherosclerosis [1, 2].  Resolution of inflammation has traditionally been regarded as a 
passive process that simply involves the abatement of proinflammatory agents.  However, 
recent findings have demonstrated that resolution is a biosynthetically active process that 
involves the activation of many tightly controlled biochemical mediators and signaling 
pathways that not only turn off the proinflammatory response, but also turn on the pro-
resolution signals [1-6].  Understanding the mechanisms of the points of control 
governing these pro resolution signals can help uncover their therapeutic potentials, 
leading to the development of novel treatment approaches for many chronic 
inflammatory diseases, including atherosclerosis.  
In this dissertation, we aim to understand the interplay between macrophage 
polarization state, macrophage motility and macrophage efferocytosis – three components 
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that are important in the resolution of inflammation – and how it relates to macrophage 
Syndecan-1 (Sdc-1) expression during inflammation.  We found that macrophage Sdc-1 
expression is associated with macrophages that display anti-inflammatory characteristics 
and are highly motile.  In fact, efferocytosis, a process that is often considered necessary 
for the successful resolution of inflammation, is found to be a regulator of macrophage 
Sdc-1 expression both in vitro and in vivo.  In addition, animal studies performed using 
mice lacking Sdc-1 expression in both peritonitis and atherosclerosis models suggest that 
the absence of Sdc-1 expression can lead to a greater inflammatory response, which is 
associated with dampened macrophage motility and efflux out of the inflammation site.  
Collectively, these results reinforce the physiological significance of macrophage 
efferocytosis and macrophage motility as endogenous modulators of the inflammatory 
response and further suggest a role for Sdc-1 in these fundamental resolution programs. 
1.2        Rationale 
 Macrophage, a monocyte-derived cell that functions as one of the key players in 
inflammation, often represents the dominant leukocyte population in chronic 
inflammation.  In fact, both early and late lesion areas in atherosclerosis consist of 
macrophage rich regions [7, 8].  Recent findings have brought into light the fact that not 
all macrophages are created equal.  In fact, macrophages are made up of heterogeneous 
population that consists of macrophages polarized to different activation state, with 
distinct biochemical activity and functions [9-14].  Thus, inflammation outcome can 
definitely be influenced by the balance between different macrophage polarization states.  
Indeed, the absence of a sufficient pro resolution macrophage counterbalance may serve 
as a driving force in the development of chronic inflammation, including atherosclerosis.  
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Additional studies that look at the involvement of macrophages in atherosclerosis have 
also indicated that dampened macrophage efferocytosis response and increased 
macrophage retention in the vascular wall are both associated with plaque progression [7, 
15-17]. These suggest that macrophage efferocytosis and egress are important factors that 
can potentially affect the resolution of inflammation.  
 Sdc-1, which is a member of a family of cell surface proteoglycans, has been 
shown to regulate events relevant to tissue repair and chronic injury responses, including 
cell migration and cell-substrate interaction [18-21].  The expression of syndecans has 
also been shown to be highly regulated by soluble growth factors that are released at the 
site of injury [22-25].  Our group has recently demonstrated that macrophage Sdc-1 
expression was upregulated and associated with a protective effect in murine model of 
abdominal aortic aneurysm (AAA) [26].  Protective effects of Sdc-1 expression have also 
been reported in other inflammatory models, including murine model of myocardial 
infarction and delayed type hypersensitivity [27, 28].  Activation of signaling pathways 
that lead to Sdc-1 expression has also been tied to anti-inflammatory G protein coupled 
receptor activation [29].  Within these diverse investigations lies a common thread 
suggesting that macrophage Sdc-1 plays a critical part in anti-inflammatory program that 
leads to the resolution of inflammation.  Therefore, understanding the role of Sdc-1 in 
dictating macrophage activation and related responses can offer new insight in the 
regulation of inflammation resolution and open up new venues for the development of 
therapeutics aimed at stimulating the resolution process.   
1.3       Central Hypothesis and Specific Aims 
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 The overall objective of this project is to understand how Sdc-1 plays a critical 
part in an anti-atherogenic program necessary for the clearance of monocyte derived cells 
out of the inflamed vascular by emigration and efferocytosis, promoting the resolution of 
inflammation.  The central hypothesis is that Sdc-1 is a critical component of a pro-
resolution program necessary for the clearance of monocyte-derived cells by emigration 
and efferocytosis, and its expression can promote resolution in inflammation and 
contribute to homeostasis.  Our overall approach to test this hypothesis is to investigate 
the relationship and interplay between Sdc-1 expression, macrophage polarization, 
macrophage motility and macrophage efferocytosis both in vitro and in vivo.  The 
specific aims for this project are: (1) characterize the role of Sdc-1 in the polarization of 
monocyte-derived subsets at sites of vascular lesion formation, and (2) define the role of 
Sdc-1 in the resolution of inflammation by promoting the emigration and/or efferocytosis 
of monocyte derived cells in the vascular wall.    
 The extent to which Sdc-1 promotes the polarization of monocyte derived cells 
and affects motility and/or efferocytosis has not been well defined.  The outcome of this 
research is expected to provide significant contribution in investigating the role of Sdc-1 
in influencing the clearance of monocyte derived cells out of the inflamed vascular wall 






 Inflammation and resolution of inflammation are two fields of research that are 
actively ongoing.  This last decade has witnessed a profound leap in our level of 
understanding in the active nature of resolution process.  The discovery of novel 
biosynthetic pathways that turn on the pro-resolution signals has lead to a surge in 
research aimed at taking a closer look at processes that can trigger resolution and 
stimulate a return to homeostasis.  In this chapter, we attempt to provide a summary of 
current knowledge in the regulation of both acute and chronic inflammation, biophysical 
processes involving macrophages that are believed to be involved in the resolution of 
inflammation, and how macrophage Sdc-1 expression can potentially affect inflammation 
outcome and help stimulate resolution.   
2.1  Inflammation: Acute vs. Chronic  
 John Hunter, an 18-th century Scottish surgeon, once wrote that “Inflammation in 
itself is not to be considered as a disease but a salutary operation consequent to some 
violence or some disease” [30].  In other words, inflammation, which is a normal 
physiological host response to infection or tissue injury, is a protective mechanism that is 
designed to neutralize harmful agents, elicit tissue healing and ultimately ensure a return 
to homeostasis.  In fact, inflammation is so life preserving that people who suffer from 
genetic deficiencies are associated with increased risk of severe infection that can be fatal 
if left untreated [31-34] .  However, the term ‘inflammation’ itself often carries a negative 
connotation and is often considered a disease that needs to be treated.  While this stems 
from the visible symptoms associated with inflammation: rubor, calor, dolor and tumor 
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(redness heal, pain and swelling), this association most likely developed from instances 
where inflammation failed to resolve and turned into a prolonged event.  Thus, it is 
important to discuss inflammation in the context of its timeframe. While acute 
inflammation is a healthy response that resolves within hours to days, chronic 
inflammation can last for weeks to months [4].  
2.1.1 Acute Inflammation 
  By design, inflammation is supposed to be an acute event.  When tissue injury 
occurs, tissue resident inflammatory cells of the innate immune system are activated, 
releasing inflammatory mediators that initiate inflammatory response.  These mediators 
can include complement, histamine, bradykinin, and cytokines and chemokines that result 
in the activation of the endothelial cells and increased vascular permeability in the area of 
injury [35-37].  During inflammation, activated endothelial cells express adhesion 
molecules, such as E-selectin, intercellular adhesion molecule 1(ICAM1) and vascular 
cell adhesion molecule 1 (VCAM1) that are presented on the luminal surface [38-40].  
These molecules aid in the recruitment of leukocytes from the bloodstream resulting in 
their rapid influx into the area of injury.  Neutrophils are short lived phagocytes that are 
among the first responders to be recruited to the inflammation site.  They participate in 
the phagocytosis and killing of the harmful microbes and also promote the recruitment of 
inflammatory monocytes that mature locally into macrophages.  Under normal 
conditions, the elimination of the harmful stimuli is followed by the apoptosis of 
neutrophils, which are then ingested and removed by macrophages.  Effective removal of 
apoptotic cells from the tissue by macrophages not only prevent further recruitment of 
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leukocytes to the inflammation site, but also stimulate macrophage egress to the 
lymphatics, leading to full resolution and complete tissue healing  [7].   
2.1.2 Chronic Inflammation 
 In instances where inflammation fails to turn off and stays activated despite the 
absence of appropriate stimulus, chronic inflammation can ultimately result.  It is now 
understood that chronic inflammation can contribute to the pathogenesis of many 
diseases, including rheumatoid arthritis, autoimmune disorders, aneurysm, and 
atherosclerosis [1, 2].  Unlike acute inflammation, where clearance of apoptotic 
neutrophils prevents further recruitment of leukocytes, chronic inflammation is 
characterized by the continuous influx of leukocytes to the injury site [7, 41].  Thus, 
chronic inflammation can result in a progressive shift of the leukocyte population to 
produce an inflammation that is dominated by macrophages instead of neutrophils.  
Activated leukocytes that accumulate at the inflammation site can also generate a lot of 
proinflammatory mediators, including proinflammatory cytokines and chemokines, 
metalloproteinases, and reactive oxygen species [7].  Overall, these factors contribute to 
the generation of proinflammatory feedback loop that keeps the inflammation from 
resolving.   
 While inflammation is a necessary process that serves as the body’s main defense 
mechanism, dysregulation of the inflammatory response can result in deleterious 
outcome.  Many check points and pathways are built into the inflammation process to 
ensure its resolution once the harmful stimuli are eliminated [2, 4, 6, 42, 43].  However, 
there are instances where these points of control become dysregulated, which then result 
in inflammation that progress unchecked.  Thus, it is important to understand these built 
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in pro-resolution check points so that we can discover where they fail and how to turn on 
and utilize them to promote resolution. 
2.2  Resolution of inflammation: molecular mechanisms 
 Resolution is an active and coordinated process that is equipped with both 
molecular and cellular mechanisms that ensure the restoration of tissue integrity and 
physiological function.  Some of these cellular signals that are essential in the resolution 
of inflammation include the expression and activation of bioactive molecules, including 
bioactive lipid mediators, adenosine, cyclic adenosine 5’-monophosphate (cAMP), 
interleukin (IL)-10 and transforming growth factor-β (TGF-β), just to name a few [1-4, 6, 
29, 42-48].  Others include active cellular functions of participating leukocytes that are 
part of the inflammatory mechanism itself, including switching/turning off of leukocyte 
activation state, apoptosis/efferocytosis and efflux to the lymphatic system [1, 7, 10, 16, 
41, 49-51] .   
2.2.1  Bioactive lipid mediators 
 Recent findings have demonstrated that specific omega-3 polyunsaturated fatty 
acid derived mediators are generated within the resolving exudates [3-6].  These include 
arachidonic acid derived lipoxin A4 (LXA4), eicosapenthaenoic acid derived resolvin E1 
(RvE1), and docosahexaenoic acid derived protectin D1 (PD1) [3-6].  LXA4 has been 
reported as a potent endogenous factor that can regulate leukocyte influx during acute 
inflammation.  Specifically, LXA4 has been shown not only as a potent regulator to stop 
neutrophil recruitment during inflammation, but also as strong stimuli for the non 
phlogistic recruitment of monocytes to the inflammation site [42, 52-54]; exposure of 
monocyte derived macrophages to LXA4 induces rapid phagocytosis of apoptotic cells 
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[2, 55, 56].  Similar to LXA4, RvE1 and PD1 have both been reported to promote the 
clearance of apoptotic neutrophils during acute inflammation by enhancing macrophage 
phagocytosis and macrophage migration to the lymphatic system [3, 5, 43, 57].  RvE1 has 
also been reported to help inflammation resolution in a variety of disease models, 
including pulmonary infection, allergic airway inflammation, dermatitis, and vascular 
disease [43, 57-59].  In a model of pulmonary inflammation, RvE1 was reported to 
accelerate resolution by promoting phagocytosis induced neutrophil apoptosis [59].  
RvE1 was also reported to ameliorate atopic dermatitis by suppressing leukocyte 
infiltration and proinflammatory cytokines production at the inflammation site [57].  
Similarly, PD1 has also been reported to be protective in many inflammatory models, 
including asthma and acute kidney injury models [60, 61].  PD1 administration was 
reported to result in significant decrease in leukocytes recruitment and proinflammatory 
cytokines production in both models [60, 61].  Overall, these bioactive lipid mediators 
possess great potential as promising therapeutic target for the resolution of inflammation 
and are the subject of various ongoing investigations.  
2.2.2 Adenosine 
 Adenosine, a purine nucleoside, is an endogenous anti-inflammatory agent that 
acts through the G-protein coupled receptor (GPCR) signaling pathway [35, 48, 62].  
Biophysical activity of adenosine is entirely dependent on its concentration level and the 
presence of its corresponding receptor [48, 63, 64]. Thus, processes that are related to 
adenosine generation, release, cellular uptake and metabolism are highly regulated during 
inflammation.  While adenosine is constitutively expressed at low concentration in the 
extracellular space, its expression can be upregulated in response to cellular insult or 
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injury [48, 63, 64].  Following its generation and release, adenosine can bind to four 
different types of adenosine receptors, including A1, A2A, A2B and A3, which are 
expressed on the surface of many types of leukocytes [48, 63, 64].  Thus, adenosine can 
target and regulate the function of many cells that are involved in orchestrating the 
inflammatory response.  
 Adenosine has been reported to have immunosuppressive effect on both 
neutrophils and macrophages.  Activation of adenosine receptors on neutrophil surface – 
all four adenosine receptors have been reported to be expressed on neutrophils – results in 
reduced neutrophil trafficking and neutrophil function [62, 65-68].  As early as the 1980s, 
adenosine has been described to be able to suppress the generation of superoxide anion 
by neutrophils [62, 65-68] .   Since then, adenosine has also been found to suppress other 
neutrophil functions, including adhesion, degranulation, and proinflammatory cytokine 
production and secretion [48, 69, 70].  In most cases, these protective effects associated 
with adenosine receptor activation are regulated through cAMP dependant pathway [48, 
71].  
 Macrophages are another type of leukocytes that express adenosine receptors on 
their surface.   Similar to neutrophils, macrophage adenosine receptor activation is 
associated with pro resolution effects on inflammation [48, 63, 64].  One of the main 
functions of macrophages, which are professional phagocytes, is to detect and clear 
harmful microbes, which can be achieved through recognition of conserved microbial 
elements by toll like receptor (TLR) or scavenger receptors [48, 72-76].  This leads to the 
generation and release of proinflammatory mediators like tumor necrosis factor-alpha 
(TNF-α), IL-12, macrophage inflammatory protein 1 alpha (MIP-1α) and nitric oxide 
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(NO) [73-76].  At the same time, the signaling pathway that govern the expression of IL-
10, a potent anti-inflammatory cytokine, is also activated [77].  However, it is important 
to note that IL-10 is not secreted until later in the inflammatory response time frame.  
One of the signals that can trigger IL-10 release from leukocytes is adenosine [77, 78].  In 
addition, adenosine also strongly suppresses macrophage production of proinflammatory 
cytokines that include IL-12 and TNF-α [79-83].  Similar to neutrophils, activation of 
adenosine signaling pathway is also linked to the cAMP pathway [29, 83, 84].  Overall, 
activation of macrophage adenosine receptor signals to macrophages that the 
inflammation state is shifting toward resolution.   
2.2.3 cAMP 
 cAMP is a second messenger that lies downstream of the GPCR signaling 
pathway.  It was discovered fifty years ago and was the first second messenger found in 
the field of signal transduction [85].  Since then, cAMP has been demonstrated to be a 
universal regulator of cellular functions that are important in the regulation of both 
physiological and pathological processes, including heart function, metabolism, cancer, 
diabetes and inflammation, just to name a few [85-89].  Macrophages are major players 
of the immune response that have been reported to be highly sensitive to cAMP 
regulation.  In brief, cAMP has been reported to have anti-inflammatory and pro 
resolution effect on macrophages [29, 45, 90].  Active biomolecules that have been 
demonstrated to increase intracellular cAMP concentration include prostaglandin E2 
(PGE2) and adenosine, as discussed above [29, 84].  Thus, adenosine and cAMP shares 
common activation pathways that result in shared features in their regulation of 
macrophage physiology.  
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Signaling through the cAMP pathway is a complex process that involves many 
chemical messengers and enzymes.  In brief, activation of GPCR leads to the 
transduction of signals which results in the activation of G proteins that activate the 
adenylate cyclase (AC).  AC then catalyzes the intracellular generation of cAMP from 
adenosine triphosphate (ATP) [45, 85].  The enzyme phosphodiesterase (PDE), which 
degrades intracellular cAMP, regulates the intracellular concentration level of cAMP [45, 
85].  Physiological effects of cAMP are mediated by two distinct intracellular receptors, 
the classic protein kinase A (PKA) and cAMP response element binding protein (CREB) 
pathway, or the more recently discovered exchange protein directly activated by cAMP 
(EPAC) pathway [85, 91-95].  Together, these two cAMP signaling pathways participate 
in the integrated control of macrophage functions during inflammation response.  
 Activation of cAMP signaling pathway has been reported to inhibit many 
macrophages inflammatory functions.  cAMP has been described to interfere with the 
generation of reactive oxygen species (ROS) that, while essential in microbial killing, can 
also result in tissue damage [45, 47, 96].  cAMP activation through the PKA pathway has 
also been described to inhibit the generation of proinflammatory mediators, including 
MIP-1α, leukotriene B4 and TNF-α  by blocking the activation of nuclear factor kappa-
light-chain enhancer of activated B cells (NF-κB) pathway in macrophages [45, 47].  
cAMP has also been found to form a multi-protein signaling complexes with A-kinase 
anchoring proteins (AKAPs) that result in the phosphorylation and activation of p105, a 
protein that can act as a cytosolic inhibitor of  NF-κB [45, 97].  Additionally, cAMP was 
also found to enhance the generation of IL-10 in LPS stimulated macrophages [45, 97].   
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 Traditionally, cAMP regulation of macrophage activity has been focused on its 
inhibitory effects on the generation and release of proinflammatory mediators.  However, 
the work performed by Kim et al has demonstrated that cAMP signaling pathway can 
also mediate macrophage migration response in anthrax model [29].  The edema factor, 
which is found in the anthrax toxin, was discovered to dramatically enhance the 
migration response of infected macrophages.  Anthrax toxin was found to activate the 
AC, which result in intracellular cAMP increase and the activation of cAMP-PKA-CREB 
signaling pathway in these macrophages [29].  The enhanced macrophage migration 
response was found to correlate with a change in macrophage cytoskeletal structure and 
cell shape in general. Indeed, activation and redistribution of actin molecules, which is 
involved in macrophage motility, was observed in these macrophages.  In addition, 
macrophages that were treated with 6-Bnz-cAMP, an analog of cAMP that specifically 
targets the PKA pathway, were found to respond in a similar manner.  Activation and 
redistribution of actin was associated with enhanced macrophage migration following 
exposure to the cAMP analog [29].  Thus, cAMP-PKA signaling pathway is associated 
with both anti-inflammatory effects and enhanced motility response in macrophages.  
2.2.4  Anti-inflammatory cytokines 
 While macrophages are crucial in the regulation of proinflammatory responses, 
they are also integral in orchestrating its resolution.  Exposure of activated  macrophages 
to apoptotic cells can trigger a shift in macrophage activation state that results in the 
turning off of proinflammatory mediators production and the activation of anti-
inflammatory mediators that include IL-10 and TGF-b [1, 17, 98, 99].  These anti-
inflammatory cytokines are important for the successful resolution of inflammation.  
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IL-10 is a well established anti-inflammatory cytokine with important 
immunoregulatory functions that can affect the functional activity of many cells that 
regulate the immune system [100, 101].  IL-10 expression is reported to be low in healthy 
tissue, but can be strongly upregulated during inflammation response. It can repress 
activated macrophage expression and release of proinflammatory mediators, such as 
TNF-α, MIP-1α, IL-6 and IL-12 [100-102].  Macrophages that have been exposed to IL-
10 can also release additional IL-10 into the microenvironment.  In this manner, IL-10 
can act in both autocrine and paracrine fashion to shift the global inflammatory 
environment toward one that is pro resolution [100, 101].   
Clearance of apoptotic cells by macrophages also triggers the release of TGF-β, 
an anti-inflammatory cytokine that regulates many cell functions, including proliferation, 
differentiation and survival [103, 104].  In inflammation, TGF-β is responsible in the 
promotion of tissue repair and regeneration [44, 46, 105].  TGF-β can stimulate 
angiogenesis, the proliferation and differentiation of fibroblast, and matrix deposition 
through the synthesis of collagen [106-110].  It can also regulate the expression of 
integrins, MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs), which are 
important in cell migration during wound healing process [46, 105, 111, 112].  Overall, 
these features all contribute to wound healing and the reestablishment of tissue integrity 
and function at the site of inflammation.    
TGF-β has also been reported to regulate the activation of other immune cells 
during inflammation, including T cells and macrophages.  TGF-β was shown to be able 
to suppress proinflammatory cytokine production, including IL-2 and interferon-γ (IFN-
γ), which results in the inhibition of activated T cell differentiation and proliferation [104, 
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113, 114].  TGF-β can also induce the activation of forkhead box P3 (Foxp3), a 
transcriptional factor necessary for the generation of regulatory T cell (Tregs) [115, 116].  
Tregs participate in the inhibition of proinflammatory cytokines generation, while also 
enhancing the expression of anti-inflammatory mediators, such as IL-10 and TGF-β [104, 
114, 117].  In addition to inhibiting T cell activation, TGF-β can also inhibit macrophage 
activation.  This can be attributed to TGB-β blocking of inducible nitric oxide synthase 
(iNOS) and MMP-12 production [118, 119].  TGF-β has also been reported to block the 
activation of TLR signaling pathway that is dependent on MyD88, which can participate 
in the production of many proinflammatory cytokines and mediators [119, 120].  Overall, 
the generation of anti-inflammatory mediators triggered by apoptotic cells at the site of 
inflammation is essential in ensuring proper wound healing and resolution of 
inflammatory response.   
2.3  Macrophage: a key player in chronic inflammation 
 In addition to the secretion of bioactive molecules that regulate inflammation 
resolution, there are active cellular processes of leukocytes that participate in 
inflammatory response themselves, that are important in resolution.  Macrophage, which 
is the main player of the mononuclear phagocyte system, is crucial in the regulation of 
inflammation.  As early as the 1980s, Elie Metchnikoff, who won the 1908 Nobel Prize in 
medicine for his work on phagocytosis, has stated the importance of the phagocytes 
stimulation in generating immune response [13, 121-123].  Generated from the 
differentiation of monocytes in the peripheral tissue, macrophages are the major 
leukocytes that are found at the site of chronic inflammation.  As mentioned previously, 
both early and late lesion areas in atherosclerosis are made up of macrophage rich regions 
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[7, 8].  In inflammation, macrophages can function as a regulator of immune response 
through the generation of proinflammatory mediators that contribute to the clearance and 
killing of harmful microbes, as a phagocyte that participates in the clearance of cellular 
debris and apoptotic cells, and as a promoter of inflammation resolution and tissue 
healing response [13, 90, 124-127].  Macrophage clearance out of the inflammation site 
to the draining lymphatic also signals the end of inflammation and a return to 
homeostasis [16, 49, 99, 128].  Thus, the regulation of macrophage activation, 
macrophage efferocytosis response and macrophage motility within the inflammation site 
are crucial in determining the outcome of inflammation.  
2.3.1 Macrophage polarization state 
Recent findings have shed light on the fact that not all macrophages are created 
equal.  Macrophages are highly plastic cells that can change their physiological features 
in response to unique environmental cues.  Microenvironmentally derived signals can 
give rise to macrophages that are polarized with specific functional properties [10, 13, 14, 
126, 129-132].  In an effort to emulate the T helper type 1/T helper type 2 (Th1/Th2) 
nomenclature of the T cell literature, macrophage polarization has been classified into 
two extremes in the linear scale of macrophage activation, which includes classically 
activated, proinflammatory M1 macrophages on one end, and alternatively activated M2 
macrophages on the other end [10, 13, 130].  The generic use of M2 was first utilized to 
describe macrophages that participate in type II immune response, tissue healing and 
remodeling and additionally share the common feature of having low IL-12 secretion [10, 
13, 14, 130].  However, current research has demonstrated that M2 polarization 
represents at least three individual subtypes that function in allergy and parasite defense 
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(M2a), immnoregulation (M2b), and tissue repair and remodeling (M2c) [10, 13, 14, 130, 
132].  Despite these classifications, given the complexity of the inflammatory 
environment and various cytokines that are released at the site of inflammation, it is 
likely that more macrophage polarization states actually exist during inflammatory 
response.      
Classically activated M1 macrophages can be generated through the exposure of 
naïve macrophages to two signals, IFN-γ and an inducer of TNF (or TNF itself) [10, 13, 
14].   IFN-γ is a proinflammatory cytokine that can be generated by both innate and 
adaptive leukocytes, including natural killer (NK) cells, activated T cells, and 
macrophages [14].  Exposure to IFN-γ, while necessary for priming macrophage 
activation, will not actually fully activate them.  A second signal that can induce TNF 
generation is necessary to fully activate the macrophages [14].  While exogenous TNF 
delivered to macrophages can result in M1 activation, TNF generation is usually a result 
of macrophage exposure to ligands that activate the TLR signaling pathway.  Exposure of 
macrophages to TLR ligands, such as microbes or microbial product (eg. 
lipopolysacciaride (LPS)), can lead to the activation of the NFκB and MyD88 signaling 
pathway, which result in the generation of TNF by the macrophages themselves [14].  
The secreted TNF will act in conjunction with IFN-γ in an autocrine manner to polarize 
macrophage to M1 activation state [14].    
Classically activated M1 macrophages serve as crucial component of the host 
defense system against foreign pathogens in the body.  M1 macrophages can be identified 
by their high surface expression level of major histocompatibility complex class II 
(MHCII) and cluster of differentiation 86 (CD86), which are essential in macrophage’s 
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role as antigen presenting cells [10, 14].   Their biological functions are also well 
documented.   M1 macrophages possess a markedly high level of antimicrobial activity 
that can be attributed to the induction of the inducible nitric oxide synthase (iNOS), 
which results in the generation of reactive oxygen species [10, 13].  M1 macrophages 
also generate high level of proinflammatory cytokines, including, TNF-α, IL-1, IL-6, IL-
12 and IL-23 [10, 13, 133].  These proinflammatory mediators are essential in driving the 
Th1 polarization which results in efficient killing of invading intracellular pathogens and 
the development of tumor resistance [10, 130, 133, 134].  Indeed, studies performed 
using mice lacking IFN-γ expression demonstrated the importance of macrophage M1 
activation state in the clearance of bacterial and viral infection [135, 136] .  The lack of 
M1 macrophage presence in various tumor environments is also associated with tumor 
growth, disease progression and metastasis [133, 134, 137].  Overall, while M1 
macrophages are vital to host defense system, their activation has to be tightly regulated, 
given the potential for excessive tissue damage to the host as a result of their secretion of 
proinflammatory mediators.    
Early in 1990s, Gordon et al made the observation that IL4 treatment resulted in 
the upregulation of mannose receptor (MR) on elicited macrophages [14, 138].  The 
authors demonstrated that these macrophages exhibited signs of activation that was 
unique compared to the classically activated macrophages [138].  This unique population 
of IL-4 treated macrophages were described as displaying an “alternative activation 
phenotype” [138].   This marks the first instance in which M2 macrophages are 
recognized to be distinct from M1 macrophages.  Since then, IL-13, another type 2 
cytokines was also found to be able to induce the alternative activation of macrophages 
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[139-142].  IL-4 has been reported to be produced by basophils and mast cells during 
early phase of tissue injury response [143-145].  It has been suggested that the secreted 
IL-4 can quickly generated M2a macrophages, which then participate in wound healing 
response [146, 147].  M2a macrophages have also been found in parasitic infection, such 
as Helminth infection, where their existence results in dampened M1 macrophage 
response [139, 148-150].  While this can lead to reduced parasite killing and clearance, 
alternative macrophages can buffer the collateral damage impacted by M1 macrophages 
[139, 148, 150].  Thus, the regulation of macrophage activation during inflammation is an 
important feature that needs to be tightly controlled.  
Studies performed on alternatively activated macrophages have demonstrated 
their distinct biochemical features and biological roles compared to the classically 
activated M1 macrophages [10, 13, 140].  IL-4 treated macrophages, which are now 
designated as M2a macrophages, display reduced antimicrobial activity compared to M1 
macrophages.  This can be attributed to their high level of arginase activity, which shares 
the same substrate, L-arginine, with iNOS; iNOS generates NO through the oxidation of 
L-arginine [151, 152].  Thus, an increase in arginase activity can result in the depletion of 
L-arginine, which then results in low NO production level.  Similar to M1 macrophages, 
M2a macrophages express high level of MHCII and CD86 [10].  However, unlike M1 
macrophages, M2a macrophages are not good at presenting antigen [10].  In fact, these 
macrophages actually inhibit Th1 response and promote the activation of Th2 response 
instead [133, 140, 148].  The high arginase activity of M2a macrophages has also been 
reported to be involved in their wound healing responses and extracellular matrix 
deposition [9, 153, 154].  High arginase activity can result in polyamine and proline 
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biosynthesis, which can result in increased production of collagen, polyamines and 
fibronectin, promoting tissue healing [9, 154, 155].  Additional features associated with 
M2a macrophages include high expression of the transcription factors, FIZZ1 and Ym1 
and the upregulation of surface expression of programmed death ligand 2 (PD-L2), a Th2 
stimulated molecule that inhibits T cell proliferation [12, 14, 156-159].  
Another macrophage polarization state was discovered when macrophage Fc 
gamma receptors (FCγRs) activation by immune complexes (IC) unexpectedly generated 
macrophages that secrete low level of IL12, but high level of IL-10; FCγRs are receptors 
found on the surface of leukocytes that can bind to the Fc portion of an antibody [14, 160, 
161].  These unique macrophages were referred to as type II activated macrophage, or 
M2b polarized macrophages.  Similar to classically activated M1 macrophages, M2b 
macrophages require two signals for their activation, FCγR ligation and macrophage 
stimulatory signals that result in cytokine production [10, 14].  This can usually be 
achieved through the activation of the TLR signaling pathway.  Type II activated 
macrophages or M2b macrophages are unique compared to M1 or M2a macrophages.  
Compared to M1 macrophages, M2b macrophages secrete low level of IL-12, though 
other cytokine production, such as TNF, IL-1 and IL-6, remain similarly high [10, 14].  
The surface expression level of MHCII and CD86 also remain high compared to M1 
macrophage [10, 14].  Compared to M2a macrophages, M2b macrophages express low 
level of arginase activity [10, 14].  However, similar to M2a, M2b macrophages also 
induce a Th2 response [10, 133].  Another interesting feature of M2b macrophages is 
their high secretion of IL-10, which is an anti-inflammatory cytokine [10, 153].  An 
adoptive transfer study, in which M2b macrophages were transferred into mice receiving 
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high dose of LPS demonstrated the protective effect of M2b macrophages [162].  Overall, 
these studies demonstrate that antibody can serve as a signal in the regulation of the 
inflammatory response. 
Another population of macrophage that is important in the resolution of 
inflammation is the regulatory macrophages, also known as M2c macrophages.  M2c 
macrophages are anti-inflammatory, pro resolution macrophages that display reduced 
MHCII and CD86 surface expression [10, 13]. M2c macrophages can arise following 
macrophage exposure to IL-10, TGF-β or glucocorticoids (GC) [10, 140, 163, 164].  GC 
is a member of the steroid hormones that can be released by adrenal cells in response to 
stressful conditions [163, 165].  The binding of GC to glucocorticoid receptor (GR) has 
been shown to result both in the upregulation of anti-inflammatory protein expression and 
in the inhibition of proinflammatory cytokine production [163, 164].  As mentioned 
previously, IL-10 and TGF-β are two anti-inflammatory mediators that can be released by 
macrophages following exposure to apoptotic cells [1, 50, 99, 166, 167].  These cytokines 
can then act in both autocrine and paracrine manner to generate M2c macrophages and 
dampen the overall immune response.   
Current research has identified four distinct macrophage polarization states in the 
murine which include M1, M2a, M2b and M2c polarization.  Despite these 
classifications, it is still unknown where these distinct polarization states actually exist in 
vivo, or whether macrophages actually exist in a spectrum of polarization states.  Given 
the complexity of the inflammation response and the multitude of cytokines that are 
released at the inflammation site, it is likely that macrophages can develop a more 
complex polarization state in vivo.  Adding to the complexity, while distinct macrophage 
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polarization states can be found in human, human macrophages have been reported to 
exhibit differences to murine macrophages in their response to polarizing stimuli [129, 
168-170].  For example, Arginase and Ym1, markers for M2a polarization state in murine 
macrophages, were not upregulated in human M2a macrophages [168, 169].  
Nevertheless, macrophages are major players of the inflammatory process and their 
manipulation can prove to be key in stimulating its resolution. 
2.3.2 Macrophage efferocytosis 
The main function of inflammation is to eliminate harmful stimuli that are 
perceived as being a threat to tissue homeostasis.  However, apoptotic cells that are 
generated in the process can be damaging to the host tissue if not removed promptly from 
the inflammation site [7, 50, 167, 171].  Apoptotic cells, if not promptly cleaned up, will 
become necrotic cells that progressively lose their cell plasma membrane integrity, 
resulting in cell swelling and eventually spilling of the intracellular toxic content onto the 
environment.  Cellular debris generated can then serve as proinflammatory signals, 
resulting in continuous leukocyte influx into the tissue, which contribute to the 
maintenance of inflammation.  Thus, macrophage ‘janitorial’ service that ensures the 
cleaning up and removal of cellular debris and apoptotic cells before they turn necrotic is 
highly essential to the resolution of inflammation [7, 13, 50, 167].   
The term efferocytosis fittingly comes from the Latin word effero meaning to take 
to the grave or to bury [15, 166].  It is a highly efficient and immunologically silent 
process by which apoptotic cells are engulfed and cleared by phagocytes, which includes 
macrophages.  While efferocytosis serves an integral part of immune response, it is also 




 of circulating neutrophils, which patrol the blood stream as a part of the body’s 
defense system , are removed and ‘recycled’ through efferocytosis every single day [15] .   
During efferocytosis, cell membrane of the phagocytes can ruffle and protrude to engulf 
the apoptotic cells, forming large, fluid filled phagosomes, also known as efferosomes 
[15, 172-175].  Macrophages recognize apoptotic cells by absence of ‘don’t-eat-me’ 
signals, which include CD47, and the expression of ‘eat-me’ signals, which include 
phosphotidylserine (PtdSer), lysophosphatidylcholine and calreticulin on their cell 
surface [15, 166, 176, 177].  Recognition of these signals by macrophage’s tethering 
receptors that include CD14 and CD31can result in the formation of phagocytic synapse.  
Further activation of the low-density lipoprotein receptor-related protein and PS receptor 
results in the activation of signaling pathway that initiates the extension of the 
phagocyte’s membrane ruffles, leading to the total engulfment of the apoptotic cells [166, 
172, 174, 175].    
One of the defining features of efferocytosis is the non immunostimulatory nature 
of the process.  On the contrary, engulfment of apoptotic cells has been shown to have an 
anti-inflammatory effect on macrophages.  Contrary to the phagocytosis of invading 
pathogens, uptake of apoptotic cells does not result in the generation of proinflammatory 
mediators.  In fact, efferocytosis has been demonstrated to have an anti-inflammatory 
effect on macrophages [16, 50].  As mentioned previously, macrophage exposure to 
apoptotic cells can trigger the secretion of anti-inflammatory mediators, including IL-10 
and TGF-β [1, 50].  Efferocytosis has also been demonstrated to dampen macrophage 
production of proinflammatory mediators such as TNF and IL-12, following exposure to 
LPS [50, 166].  In fact, efferocytosis can have such immunosuppressive effects that it is 
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utilized in apoptotic cell-based therapy as an approach to prevent or to treat allograft 
rejection and graft versus host disease in transplantation [178-180].   
Another study also found that efferocytosis can affect macrophage motility during 
inflammatory response.   Utilizing a murine peritonitis model, it was found that a unique 
macrophage population expressing low level of CD11b was present during the resolution 
phase of the inflammation [99].  The CD11b
low
 macrophages display unique features 
compared to their CD11b
hi 
macrophage counterpart, including expressing lower level of 
iNOS, MMP-9 and displaying dampened inflammatory response to TLR stimulation [99].  
In addition, these macrophages were found to be more likely to egress to the draining 
lymphatics compared to the CD11b
hi 
macrophages [99].  Significantly, CD11b
low
 
macrophages were found to have engulfed more apoptotic cells compared to the CD11b
hi 
macrophages.  In fact, subsequent exposure of CD11b
hi
 macrophages to apoptotic cells 
can result in the reduction of surface CD11b expression [99].  Overall, this suggests that 
apoptotic cell exposure can alter macrophage phenotype into one that is more motile and 
more pro resolution.  
Some of the turning points in inflammatory response that signal the shift from 
inflammation to resolution are the apoptosis of infiltrating leukocytes and their clearance 
by macrophages via efferocytosis.  In addition, subsequent macrophages egress from the 
inflammation site is essential to achieve full resolution and a return to homeostasis.  This 
suggests that macrophage motility is potentially another factor that is important in 
determining the outcome of inflammation.   
2.3.3 Macrophage motility: chemokine and chemokine receptor 
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Leukocyte migration is an important factor in the regulation of inflammation.  
Early in the inflammatory response neutrophils are recruited from the bloodstream into 
the injured tissue where they release proinflammatory factors that result in the further 
recruitment of inflammatory monocytes to the site.  Subsequently, macrophage migration 
out of the inflamed tissue into the draining lymphatics is crucial in achieving full 
inflammation resolution.  While a lot has been studied regarding the regulation of 
neutrophils and monocyte influx into inflammation site, not as much is known regarding 
macrophage migration within the tissue and macrophage efflux to the lymphatics during 
resolution.  The recent paradigm shift whereby the active nature of resolution is 
recognized has lead to the notion that the regulation of macrophage motility during 
inflammation response is not as trivial as it was once believed and can in fact be 
important in determining inflammation outcome.   
Leukocyte migration is governed through the expression of chemokine receptors 
and chemokines.  Chemokine receptors are superfamily of GPCRs containing seven 
transmembrane domains that are almost exclusively expressed on leukocytes [10, 37, 
181].  Each family of chemokine receptor can bind with their corresponding family of 
chemokines, a group of low molecular weight proteins that serve as chemoattractant.  
While chemokine – chemokine receptor interaction has been reported to be involved in 
organ development, angiogenesis, malignancy, and human immunodeficiency virus 
(HIV) infection, its traditionally defined role has been to control leukocyte trafficking in 
immune response and inflammation [182-188].   
Chemokine – chemokine receptor interaction is responsible in controlling the 
migration of circulating monocytes from the circulation into their target tissues.  Similar 
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to macrophages, monocytes are also comprised of heterogeneous populations.  Current 
research has indicated that there are at least two monocyte subsets that exist in the murine 
system.  Resident monocytes expressing high level of CX3C receptor (CX3CR)  type 1,  







) are targeted into a variety of non-inflamed tissues where they serve as precursor to 
resident macrophages [189-191].  In contrary, high level of CCR2, high level of Ly-6C 







) can direct their migration into injured tissues during inflammation [189-191].  









 monocytes that display similar homing potential as their 
murine counterpart [189, 190, 192].  Despite extensive amount of research that has been 
done to characterize monocyte chemokine receptor expression and monocyte trafficking, 
not as much is known about chemokine receptor expression pattern once monocyte reach 
the target tissue and mature into macrophages.  In addition, it is also likely that 
macrophage chemokine receptor expression pattern, and thus, macrophage motility can 
be affected by their polarization states.  
Distinct macrophage polarization states are associated with unique macrophage 
chemokine secretion pattern [10].  Classically activated M1 macrophages have been 
reported to secrete many proinflammatory chemokines that actively recruit leukocytes 
including proinflammatory monocytes, neutrophils and activated T cells into the 
inflammation site [10, 182].  Activation of the TLR signaling pathway results in the 
transcription of  NF-κB dependant chemokines, including  CXC chemokine ligand 
(CXCL) 1,2,3,5,9, and 10, CC chemokine ligand (CCL) 11, 17 and 22, and IL-8, 
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monocyte chemoattractant protein-1 ( MCP-1), macrophage inflammatory protein-1α 
(MIP-1α) MIP-1β, regulated on activation, normal T cell expressed and secreted 
(RANTES) [10, 13].  On the contrary, activation of the M2a and M2c polarization states 
results in the inhibition of proinflammatory chemokines secretion.  IL-4 and IL10 have 
been reported to inhibit the production of CXCL9, CXCL10 and RANTES through the 
inhibition of NF-κB pathway [1, 10, 193].  In addition to inhibiting proinflammatory 
chemokines generation, M2 macrophages can also secrete chemokines that recruit 
immune cells involved in Th2 responses, tissue repair and remodeling and 
immunoregulation [10].  M2a macrophages produce CCL17, 18, 22 and 24, which can 
recruit basophils, eusinophils, and Th2 cells and regulatory T cells (Treg) [10, 194, 195].  
M2b macrophages have been reported to produce CCL1, which can recruit eosinophils, 
Th2 cells and T reg [10].  Lastly, M2c macrophages can produce CCL16, CCL18 and 
CXCL13, which can recruit eosinophils [10].  Overall, chemokines produced by M2 
macrophages promote the recruitment of leukocytes that display anti-inflammatory 
effects compared to the proinflammatory nature of chemokines produced by M1 
macrophages.  
Compared to monocytes, the chemokine receptor expression pattern on 
macrophages is not as understood.  In addition, given the diversity and complexity of 
macrophage polarization states, chemokine receptor expression patterns on these 
macrophages are likely to be just as complex. M2a macrophages have been reported to 
express CXC receptor (CXCR) type 1and CXCR2 that are functionally active [10].  M2c 
macrophages have been reported to display higher expression level of both CCR2 and 
CCR5, which are proinflammatory chemokine receptors [10, 196].  However, these 
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macrophages do not migrate toward the corresponding ligands.  In fact, it was reported 
that CCR2 and CCR5 expression on M2c macrophages serve to act as decoy receptors 
that function to scavenge the proinflammatory ligands from the environment [10, 197].  
Some earlier reports have also reported CCR7 as a marker for pro resolution 
macrophages that participates in macrophage egress from the atherosclerotic plaque to 
the nearby draining lymphatics [198, 199].  However, further research has shown that 
CCR7 may not be involved in this process [41].  In fact, CCR7 gene expression has been 
demonstrated to be upregulated in classically activated M1 macrophages [129, 200].  
Overall, not much is known regarding the chemokine receptor expression pattern on 
macrophages and how it relates to their polarization states.  
2.3.4 Macrophages in chronic inflammatory disease: atherosclerosis 
Macrophages are central in the execution of host’s immune response.  However, 
as mentioned previously, defects in macrophage biochemical functions including the 
regulation of macrophage polarization, efferocytosis and migration responses can result 
in the generation of macrophages that are pathogenic.  Atherosclerosis is a chronic 
vascular disease that is characterized by continuous recruitment of proinflammatory 
monocytes into the lesion site [7, 16, 17, 167, 201].  This can result in the accumulation 
of activated macrophages in the vascular wall, which contributes to the maintenance of a 
high level of proinflammatory mediators like proinflammatory cytokines, reactive oxygen 
species and proteases in the global environment.  Recent study performed by Khallou-
Laschet et al has indicated the presence of a progressive shift in macrophage polarization 
during atherosclerosis progression, with M2 macrophages dominating early lesion and 
M1 macrophages dominating late, advanced lesion [202].  In addition, the combination of 
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high leukocyte presence, which eventually turns apoptotic, and defective efferocytosis, 
eventually results in the generation of necrotic core within the vascular wall [7, 167].  
Overall, this combines to create an inflammatory environment with a massive M1/M2 
macrophage imbalance.  Another recent publication by van Gils et al also highlighted the 
importance of macrophage motility in atherosclerosis [203].  It was found that netrin-1 
secretion in atherosclerotic plaque could block macrophage migration toward select 
chemokines which then resulted macrophage retention in the vascular wall, leading to 
atherosclerosis progression [203].  Conversely, deletion of netrin-1 was associated with 
increased macrophage egress and reduced plaque burden [203].  Overall, these studies 
suggest that macrophages can have a major impact on inflammation outcome.  Given the 
recent understanding of the active nature of resolution process, more effort is being 
invested into understanding where the pro resolution mechanisms fail in chronic disease 
like atherosclerosis and what can be done to reverse chronic inflammation.  
Recently, our group has discovered a unique population of macrophages that 
express Sdc-1 in murine AAA disease model [26].  Macrophage Sdc-1, which has been 
described to participate in the regulation of cell adhesion and motility, was found to be 
protective in this model.  This agrees with other reports, including studies conducted in 
murine DTH and myocardial infarction, where Sdc-1 expression has been found to be 
protective [27, 28].  Thus, Sdc-1 expression can potentially be important in the regulation 
of macrophage functions and thus affects the inflammation outcome.   
2.4   Syndecan-1 in inflammation 
Syndecans are a family of type I transmembrane heparan sulfate and chondroitin 
sulfate proteoglycans that consist of 4 family members, Sdc-1, -2, -3 and -4 [18-20].  
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Syndecans consist of an extracellular domain that is decorated with sulfated sugar chains, 
a short transmembrane domain, and an intracellular domain that is highly conserved 
across the different members and across different species.  Syndecans are known to be 
expressed on various cell types throughout many different stages of developments.  
While Sdc-1 is normally expressed on endothelial cells and plasma cells surface in adult 
tissues, its expression on other cell types can be induced by soluble growth factors, such 
as TGF-β, that are released at the site of injury [22-25, 79].  Sdc-2 can be found on 
mesenchymal cells and endothelial cells, while Sdc-3 can be found mostly on neural cells 
[19, 20]. Lastly, Sdc-4 is expressed on most cell types, though at a lower level than other 
syndecans [19, 20].   
Through its heparan sulfate sugar chain, syndecans can bind and regulate the 
activity of many soluble and insoluble ligands, including extracellular matrix (ECM) 
components (e.g. fibronectin, collagen), growth factors (e.g. fibroblast growth factor 
(FGF), TGF-β, platelet derived growth factor (PDGF)), proteases (e.g. MMP-1,2,9, 
cathepsin G, neutrophil elastase), and cytokines(eg. IL-8) and chemokines (eg. IFN-γ, 
RANTES, MIP-1α, MIP-1β) [18, 204].  Syndecans can influence these ligands’ 
biological functions by affecting their availability, stability and compartmentalization 
[18, 205].  Thus, through its role as a cell surface co-receptor, syndecans are able to 
regulate events relevant to tissue repair and chronic injury responses, which include cell 
migration and proliferations, cell-substrate interactions, wound healing and matrix 
remodeling.   
Within the syndecan family, Sdc-1 is emerging to be an important regulator of 
inflammatory response. Several studies utilizing Sdc-1
-/-
 animals have described the 
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potential role of Sdc-1 in regulating leukocyte recruitment during inflammation [28, 206, 
207].  In a murine model of DTH, which is commonly used to study cell-mediated 
immune responses, absence of Sdc-1 expression was associated with prolonged 
inflammation, increased infiltration of leukocytes, and increased production of 
proinflammatory cytokines, including TNF-α, Il-6 and RANTES [28].  Similarly, in a 
murine model of nephritis, increased leukocyte adhesion and recruitment, increased 
proinflammatory cytokines production and impaired would healing response were 
observed in the absence of Sdc-1 [206].  Studies in animal model of toxic shock also 
demonstrated similar outcomes [207].   
Sdc-1 has also been described to affect the wound healing responses in several 
inflammatory disease models. In a myocardial infarction model, mice lacking Sdc-1 
expression demonstrated abnormal tissue healing, characterized by fragmented collagen 
fibers, which was attributed to higher MMP proteolytic activity in the tissue [27].  On the 
other hand, increased Sdc-1 expression was reported to attenuate the inflammatory 
response, improve tissue healing and protect against cardiac dysfunction [27, 208]. 
Recent publication from our research group also demonstrated that the absence of Sdc-1 
resulted in the exacerbation of AAA progression [26].  Sdc-1 absence was resulted in 
increased elastin degradation and increased MMP proteolytic activity in the vascular 
wall.  Increased leukocyte infiltration into the vascular wall was also observed.  Overall, 
these studies suggest that Sdc-1 expression during inflammation can result in dampened 
inflammatory responses. 
Of particular interest is the expression of Sdc-1 on macrophages. Activation of the 
cAMP-PKA signaling pathway, which is one of the cellular signaling pathways that 
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participates in the resolution of inflammation, has been shown to regulate macrophage 
Sdc-1 expression [29, 209]. The work performed by Kim et al has also demonstrated the 
involvement of this particular signaling pathway in the regulation of macrophage 
migration response in anthrax, as mentioned previously [29].  Indeed, Sdc-1 was found to 
be one of the downstream targets activated via the cAMP-PKA pathway in macrophages 
following their exposure to the anthrax toxin.  It was also confirmed that macrophage 
migration response following anthrax toxin exposure was significantly impaired in the 
absence Sdc-1 expression. Given the importance of macrophage motility in ensuring 
successful inflammation resolution, Sdc-1 can potentially be an important factor in the 
regulation of inflammation.   
2.5 Summary 
The extent to which Sdc-1 affects macrophage polarization and functions has not 
been well defined.  Recent findings have brought into light the active nature of the 
resolution of inflammatory response, which involves both emigration and efferocytosis of 
monocyte derived cells out of the site of inflammation through nearby lymphatic vessels. 
Both of these processes may be impaired in chronic inflammatory diseases, which are 
usually associated with accumulation of macrophages at the disease site.  While the 
mechanisms for impaired efferocytosis and emigration remain to be determined, the 
failure of macrophages to switch to a phenotype that express Sdc-1 may contribute to 
impaired motility and phagocytic function, which subsequently contributes to the 
maintenance of chronic inflammatory state. Thus, it is important to understand how Sdc-1 
expression influences the clearance of monocyte derived cells out of the inflamed 
vascular wall, promoting resolution.  This can also offer new insight in the regulation of 
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inflammation and lead to the discovery of pathways that can be utilized to promote its 
resolution.   
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CHAPTER 3 
SYNDECAN-1 EXPRESSION ON MACROPHAGES IS 
PROTECTIVE IN ATHEROSCLEROSIS AND IS ASSOCIATED 
WITH M2 POLARIZATION STATE AND EHANCED MOTILITY 
 
Sdc-1 expression has been reported to be protective in many inflammatory 
diseases.  Recently our group has reported that macrophage Sdc-1 expression is 
upregulated and is protective during the progression of AAA.   Despite these reports, the 
mechanisms by which Sdc-1 promotes the polarization of monocyte derived cells and 
their functions have not been well defined.  Given the important role that macrophages 
play during the course of inflammatory response and their abundance in chronic 
inflammatory diseases, we seek to define the mechanisms by which Sdc-1 expression can 
alter macrophage functions and affect inflammation outcome.  The effects of macrophage 
Sdc-1 expression on inflammation outcome will also be examined in a murine model of 
atherosclerosis 
3.1 Introduction  
 Atherosclerosis is a chronic cardiovascular disease that serves as the number one 
killer in developed countries and is quickly becoming the major cause of deaths in many 
developing countries [201, 210, 211].  In the United States alone it accounts for more 
than 1 million deaths, while worldwide, it is responsible for more than 19 million deaths 
annually [210, 211].  Atherosclerosis progresses over the course of many years and in 
many cases, is asymptomatic during its early stages.  It is characterized by progressive 
 35 
thickening and narrowing of the blood vessel, which results in the gradual blocking of the 
arteries, compromising blood flow in the process.  Consequently, atherosclerosis can 
serve as the underlying cause of many cardiovascular diseases, including myocardial 
infarction, strokes and peripheral artery disease [210, 212].  
   Unlike acute cases of inflammation, where leukocytes ultimately leave the site of 
inflammation, atherosclerosis is characterized by the persistence of activated 
macrophages that fail to leave the atherosclerotic plaque.  Key processes necessary for 
the resolution of inflammation, including decreased influx of inflammatory cells 
efferocytosis, and macrophage egress from the inflammation site have all been shown to 
be defective in advanced atherosclerotic lesions [7, 167].  This can result in the 
accumulation of apoptotic cells in the plaque, secondary necrosis, necrotic core 
generation and recruitment of additional monocytes that mature into proinflammatory 
macrophages in the lesion. [7, 167].   At the same time, the clearance of inflammatory 
macrophages and the generation of anti-inflammatory cytokines associated with the 
efferocytosis process are also diminished.  Overall, these result in the maintenance of a 
proinflammatory environment and the generation of a pro-atherosclerotic inflammatory 
feedback loop that stimulates plaque progression. 
Macrophages often represent the dominant leukocyte population in chronic 
inflammation; in atherosclerosis both early and late lesion areas consist of macrophage 
rich regions [7, 8].  Microenvironmentally derived signals can give rise to distinct 
macrophage subsets that are polarized with specific functional properties, including 
classically activated, proinflammatory M1 macrophages, and alternatively activated M2 
macrophages [10, 13, 14, 129, 132, 140].  M2 macrophages can be further categorized 
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into at least 3 individual subtypes functioning in allergy and parasite defense (M2a), 
immunoregulation (M2b), or tissue repair and remodeling (M2c) [10, 13, 14, 130].  
Recent studies indicate that distinct macrophage subsets are present in mouse models of 
atherosclerosis; early lesions have been associated with M2 macrophages, while more 
advanced atherosclerosis is associated with an M1 phenotype [202].  Indeed, this suggests 
that lesion progression may correlate with M1:M2 ratio and the balance between these 
different subsets may affect the dynamic and outcome of the disease.  While regression of 
atherosclerosis lesion is not commonly found in human cases, studies using murine 
models of atherosclerosis have indicated that regression can be achieved under certain 
conditions.  Robust lipoprotein profile change, achieved through transplantation of 
atherosclerotic arterial segment from Apolipoprotein E (ApoE)
-/- 
mice to wild type (WT) 
recipients has been shown to result in rapid atherosclerosis regression, which was 
explained by emigration of foam cells from the lesion to the lymph nodes [198].  More 
recent study using an ApoE complementation model also indicated that plaque regression 
could be linked to suppressed monocytes recruitment into the atherosclerotic plaque [41].  
A recent report from van Gils et al described the expression of the negative guidance cue 
netrin-1 in foam cells; netrin-1 was found to promote macrophage retention through 
inhibition of cytoskeletal reorganization, effectively blocking directed migration [203].  
Notably, targeted deletion of netrin-1 improved macrophage emigration and 
atherosclerotic outcomes.  Overall, these findings reveal that dampening inflammatory 
influx and restoring macrophage motility potential in the lesion may facilitate 
macrophage egress and plaque regression 
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Syndecan-1 (Sdc-1) is a member of a family of cell surface proteoglycans that has 
been reported to participate in the regulation of events relevant to tissue repair and 
chronic injury responses, including cell-substrate interactions, matrix remodeling and cell 
migration and proliferation [19-21, 204].  Sdc-1 expression, which can be highly 
regulated by soluble growth factors that are released at the sites of injury, has been 
reported to be protective in various inflammatory models, including delayed type 
hypersensitivity, nephritis, toxic shock, myocardial infarction and abdominal aortic 
aneurysm (AAA) [26, 28, 206-208].  Expression of Sdc-1 on macrophages, which we 
have previously demonstrated to be protective in the murine AAA model, is of particular 
interest, given the important role that macrophages play in atherosclerosis inflammation 
[26].  Of note, induction of macrophage Sdc-1 expression is controlled through the 
cAMP/ protein kinase A signaling pathway, which has been shown to be anti-
inflammatory [29, 209].   
In this chapter, we aim to define the functional role of Sdc-1 in atherosclerosis.  
Using a murine atherosclerosis model, we have identified the presence of a macrophage 
subset in the atherosclerotic wall that expressed Sdc-1.  Deficiency in Sdc-1 expression 
was found to exacerbate wall inflammation, which resulted in increased plaque burden.  
In vitro characterization of murine Sdc-1
+
 macrophages, which can be generated through 
the activation of cAMP/protein kinase A signaling pathway or through exposure to 
adenosine, indicates that Sdc-1 expression defines an anti-inflammatory population with 
high motility.  We also found that the absence of Sdc-1 was associated with defective 
actin reorganization, which resulted in dampened macrophage migration.  Analysis of 
human macrophages confirmed Sdc-1 expression in an alternatively activated, motile 
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population.  In addition, we identified Sdc-1 positive macrophages in human 
atherosclerotic plaque.  Collectively, these results reinforce the physiological significance 
of macrophage motility as an endogenous modulator of inflammatory response and 
further suggest Sdc-1 as a crucial component in the regulation of macrophage motility 
response. 
3.2 Results 
3.2.1 Macrophage associated Sdc-1 expression attenuates atherosclerotic lesion 
formation 
Administration of high fat Western diet to ApoE
-/-
 mice has been demonstrated to 
significantly accelerate atherosclerotic plaque formation. To evaluate the involvement of 
macrophage Sdc-1 expression during atherosclerosis progression, ApoE
-/-
 mice were 
maintained on high fat Western diet for 8 weeks.  Immunohistochemistry was then 
utilized to characterize Sdc-1 expression in concert with macrophage infiltrate within the 
atherosclerotic plaque obtained from the animals.  We found that Sdc-1 expression was 
upregulated within the atherosclerotic plaque, with most Sdc-1 positive cells localized to 
the intima and adventitia, while little to no expression of Sdc-1 was detectable in the 
native aorta (Fig.3.1A).  In addition, we observed an association between macrophage 
and Sdc-1 positive staining, which was confirmed by double immunofluorescence 
staining.  As illustrated, Sdc-1 expression was found to colocalize with Mac-3 positive 
cells, consistent with the notion that Sdc-1 expression was specific to infiltrating 





 mice were enrolled in the study and immunohistochemistry 
was then utilized to characterize macrophage infiltration within the plaque.  Sdc-1 
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deficient mice have been previously characterized as healthy, with normal growth, 
reproduction, tissue morphology, hematologic profile and serum chemistry parameters 
[207, 213].  We observed an increase in the atherosclerotic lesion size in the absence of 







 mice (Fig.3.1C).   Overall, these results suggest that 
deficiency in Sdc-1 expression can exacerbate vascular wall inflammation, which results 




Figure 3.1.  Macrophage expressed Sdc-1 attenuates experimental atherosclerosis lesion 
formation.  A. Immunohistochemistry staining of Sdc-1 within the atherosclerotic plaque 
following 8 weeks of high fat diet and in control aorta.  B. Representative images 
showing immunofluorescence staining of macrophages (Mac3, Alexa 594, red), Sdc-1 
(fluorescein, green) and  4’,6-diamidino-2-phenylindole nuclear stain (DAPI, blue) within 







 mice following 8 weeks of high fat diet.  The extent of 
lesion formation was reported as lesion area (n=19).  *P<0.05.  All data represent the 





3.2.2 Sdc-1 is expressed on macrophages displaying M2 characteristics 
Given the observed importance of macrophage expressed Sdc-1 to the localized 
inflammatory response, we sought to define the functional polarization state of 
macrophages expressing Sdc-1.  Initial studies to characterize the polarization of Sdc-1
+ 
macrophages were performed utilizing flow cytometry to define the cell surface 
expression of MHCII, CD86 and PD-L2;both MHCII, an antigen presenting molecule, 
and CD86, a co-activating molecule, have been reported to be upregulated on M1 and 
M2b macrophages [10], while PD-L2, a Th2 stimulated molecule that inhibits T cell 
proliferation, has been reported to be highly upregulated on M2a macrophages and to a 
lower extent, on M1 macrophages [156].   While the presence of M1 and M2 like 
macrophages in atherosclerotic plaque has been previously demonstrated, the 
involvement of immune complexes, necessary for the generation of M2b macrophages, in 
atherosclerosis progression has not been widely reported [202, 214],  Thus, we opted to 
characterize MHCII, CD86 and PD-L2 surface expression on Sdc-1 enriched 
macrophages and polarized standard populations, which include: (i) classically activated  
M1 (Ifn-γ and LPS treated), (ii) alternatively activated M2a (IL-4 treated), and (iii) 
regulatory M2c (IL-10 treated).  Biochemical and functional activities, such as generation 
of nitrite, arginase activity, generation of IL-10 and phagocytosis activity were also 
characterized.  Macrophage Sdc-1 induction in vitro was achieved using cAMP or 
adenosine treatment (Fig.3.2A).  While macrophage Sdc-1 expression in response to 
cAMP-PKA signaling pathway activation has been shown previously [209], macrophage 
Sdc-1 expression in response to adenosine, an endogenous anti-inflammatory agent that 
exerts anti-inflammatory effects on macrophages, has not been well characterized.  Flow 
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cytometry analysis of control macrophage populations showed that Sdc-1 was not 
expressed on M1, M2a or M2c macrophages (Fig.3.2B).  While we have identified 2 in 
vitro conditions to induce Sdc-1 expression, subsequent subtype characterizations was 
performed using adenosine induced Sdc-1 expression, unless noted otherwise.  As 
expected, M1 polarized macrophages displayed characteristically high expression of 
MHCII, and CD86 (Fig.3.2C).  M2a polarized macrophages were characterized as CD86
+
 
with high expression of PD-L2 (Fig.3.2C).  However, M2c macrophage does not 
positively correlate with MHCII, CD86 or PD-L2 (Fig.3.2C), consistent with reports that 
IL-10 deactivates macrophages [156].  Sdc-1 expressing macrophages, which can be 
enriched after treatment with a cAMP or adenosine, displayed strongest similarity to M2c 






 signature (Fig.3.2C).   
Macrophage populations were further characterized for soluble mediators.  We 
found elevated nitrite level only in M1 population (Fig.3.2D), while arginase activity was 
enhanced only in M2a population (Fig.3.2E).  We observed a significant increase in IL-
10 secretion in our Sdc-1
+ 
population, though not as high as M2c macrophages 
(Fig.3.2F).  Finally, we characterized phagocytosis, which has been reported to be 
upregulated in M2 macrophages [163, 215, 216], and found that activity was significantly 
elevated in all populations compared to M1 (Fig.3.2G).    
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Figure 3.2A-C.  Macrophage Sdc-1 expression is associated with alternatively activated 
M2 polarization state.  A. Sdc-1 expression was analyzed on murine peritoneal 
macrophages following exposure to cAMP (100µM) or adenosine (Ado,375 µM).  B. 
Sdc-1 expression was measured on M1 (IFN-γ, 100U/mL + LPS, 100ng/mL), M2a (IL-4, 
20ng/mL), and M2c (IL-10, 100ng/mL) polarized standard population.  C.   Sdc-1 
expressing macrophages were examined against standard populations for surface 
expression of M1 (MHCII, CD86) and M2a (PD-L2) markers.  Expression level was 
quantified as mean fluorescence index (MFI) (filled: IgG control, black line: 















Figure 3.2D-G.  Sdc-1 expression is associated with alternatively activated M2 
polarization state.  D.  iNOS activity was characterized via Griess reaction using 
conditioned media of M1, M2a, M2c and Sdc-1
+
 macrophages (n=3). **P<0.01.  E.  
Arginase activity was measured from conditioned media of polarized macrophages and 
measured as fold increase compared to unstimulated peritoneal macrophages (n=4-5). 
*P<0.05.  F. IL-10 was measured from the conditioned media of immunostimulated M1, 
M2a, M2c and Sdc-1
+
 macrophages using ELISA (n=3).  **P<0.01.  G. Phagocytosis of 
M2a, M2c and Sdc-1
+
 macrophages was compared against M1 macrophages.  % 
phagocytosis was quantified through fluorescent bead uptake and analyzed using FACS 






macrophages display low leukocyte chemo-attractive potential compared 
to M1 macrophages  
Although it is a challenge to effectively categorize Sdc-1 expressing macrophages 
into any previously defined M2 subtype, it is clear that Sdc-1 expression is not consistent 
with a classically activated M1 phenotype and subsequent quantitative real-time reverse 
transcription polymerase chain reaction (PCR) confirmed this distinction.  As expected, 
higher level of proinflammatory genes and chemokines were expressed in M1 compared 
to Sdc-1 enriched macrophages (Table 3.1 and 3.2).  Given the impact that leukocytes 
recruitment can have on inflammation outcome, we examined the chemo-attractive 
potential of conditioned media generated from M1 or Sdc-1 enriched populations toward 
purified circulating monocytes or activated CD4 T cells.  Circulating monocytes, which 
mature into macrophages in the tissue, and activated CD4 T cells have both been 
demonstrated to be actively recruited into the atherosclerosis plaque [41, 217].   As 
expected, we observed significantly reduced migration response from both monocytes 
and T cells to conditioned media obtained from Sdc-1
+
 macrophages compared to 
condition media obtained from M1 macrophages (Fig.3.3).  This result suggest that while 
M1 macrophages can contribute to the progression of inflammation through its 
recruitment of inflammatory leukocytes, Sdc-1
+
 macrophages can  dampen inflammatory 
response by limiting leukocyte recruitment into the inflammation site. This finding also 
suggests that macrophage Sdc-1 expression should correlate with reduced inflammatory 




Table 3.1  mRNA expression profile of inflammatory genes in M1 compared to Sdc-1
+
 
macrophages.  RNA was extracted from M1 or MACS enriched Sdc-1
+
 macrophages and 
analyzed on the chemokines and receptors RT1 profiler PCR array; expression were 












 Gene Information 
GM-CSF 29 Granulocyte differentiation factor 
IL1α 14 Proinflammatory cytokine 
NFκβ 6 Transcription factor for many inflammatory genes 
MyD88 5 Adapter protein that participates in the activation of NFκβ 
TNFα 103 Proinflammatory cytokine 
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Table 3.2  mRNA expression profile of chemokines in M1 compared to Sdc-1
+
 
macrophages.  RNA was extracted from M1 or MACS enriched Sdc-1
+
 macrophages and 
analyzed on the chemokines and receptors RT1 profiler PCR array; expression were 





 Gene Information 
CCL2/MCP1 78 Monocyte chemoattractant 
CCL4/MIP1β 60 Induce neutrophil superoxide production 
CCL5/RANTES 354 TNFα and IL1β inducible, T cell recruitment 
CCL7/MCP-3 100 Monocyte recruitment 
CCL8/MCP-2 27 Monocyte, T cell and NK cell recruitment 
CCL12/MCP-5 834 Monocyte recruitment 
CXCL1 32 Neutrophil and monocyte recruitment 
CXCL2 67 Neutrophil recruitment 
CXCL9 99,768 IFN-ɣ inducible, T cell and monocyte recruitment 
CXCL10 5,019 IFN-ɣ inducible, T cell and NK cell recruitment 






Figure 3.3.  Sdc-1 expression is associated with reduced leukocyte chemoattractive 
potential.  Leukocyte chemoattractive potential was measured by transwell chemotaxis of 
A. murine circulating monocytes and B. murine activated CD4 T cells to conditioned 
media from M1 or Sdc-1
+
 macrophages. Cells that migrated to the lower chamber were 
counted and reported as % migrated (n=3). *P<0.05, **P<0.01.  All data represent the 





3.2.4 Macrophage Sdc-1 expression is associated with reduced plaque inflammation 
Our study utilizing murine atherosclerotic model indicates that Sdc-1 plays a 
protective role in atherosclerosis progression, which is supported by our in vitro 
characterizations of Sdc-1
+
 macrophages.  To evaluate the effect of Sdc-1 expression on 
the global inflammatory environment within the vascular wall, immunohistochemistry 







mice.  As mentioned previously, we observed discrete 
regions of Sdc-1 expression, which was co localized with macrophages in the intima and 
adventitia region.  In contrast, we observed a different iNOS expression pattern within 
the plaque which indicated that distinctiveness of the Sdc-1
+
 macrophages from the M1 





mice suggested an exaggerated inflammatory response in the absence of 
Sdc-1 expression (Fig.3.4).  .  
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Figure 3.4.  The absence of Sdc-1 expression is associated with increased inflammatory 







 mice following 8 weeks of high fat diet.  B. The extent of 
iNOS expression was reported as % of plaque area (n=3).  *P<0.05.  All data represent 







3.2.5 Each macrophage polarization state is associated with distinct motility and 
adhesion response, which is both reduced in the absence of Sdc-1 expression 
While our findings support the hypothesis that Sdc-1 expression on macrophages 
is indicative of a M2 polarization state, the mechanisms by which this protective effect 
can be achieved in vivo is unknown.  Given that Sdc-1 has been traditionally studied in 
the context of cell adhesion and migration, it is likely that Sdc-1 expression can affect 
macrophage motility response.  Macrophage intrinsic motility was first investigated by 
looking at the migration of M1, M2a, M2c and Sdc-1
+
 macrophages toward fetal bovine 
serum (FBS) using a transwell chemotaxis experimental setup.   To investigate the effect 
of macrophage Sdc-1 expression on motility, the experiment was also performed using 
Sdc-1
-/- 
macrophages.  M1 macrophages displayed significantly attenuated migration 
response toward FBS compared to M2 and Sdc-1
+
 macrophages (Fig.3.5A).  In addition, 
motility was also found to be significantly reduced in the absence of Sdc-1 expression 
(Fig.3.5.B).  We next investigated whether macrophage adhesion was related to the 
altered intrinsic motility associated with different polarization states and Sdc-1 




 macrophages to 
fibronectin coated surface. Result from this experiment suggested that reduced intrinsic 
motility in macrophages was associated with increased adherence.  M1 and Sdc-1
-/-
 
macrophages both displayed significantly stronger adhesion compared to macrophages 
expressing Sdc-1 (Fig.3.5C).  The regulation of cell motility and cell adhesion is closely 
associated with cytoskeletal activation.   The actin cytoskeleton has been reported to be 
important in the regulation of macrophage migration  response [218].  Consistent with the 
reduced intrinsic motility, absence of Sdc-1 was associated with reduced actin activation 
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in response to adenosine exposure (Fig.3.5.D).  These findings suggest that macrophage 
motility is potentially an additional mechanism by which macrophages orchestrate the 
inflammatory response.  In addition, Sdc-1 expression on macrophages can serve as an 





Figure 3.5.  Polarized macrophages display distinct migration and adhesion.  A-B 
Intrinsic motility was analyzed using transwell migration to FBS.  Polarized macrophages 
were placed into the upper chamber of a transwell and macrophages that migrated to the 
lower surface of the membrane was stained, counted and reported as migration index.  A. 
Intrinsic motility of standard populations and Sdc-1
+
 macrophages (n=4).  **P<0.01.  B. 




 macrophages (n=5).  *P<0.05.  C. Macrophage 




macrophages that was allowed to adhere onto fibronectin coated surface (n=3-4).  




macrophages were treated with adenosine and stained 





3.2.6 Efferocytosis as a regulator of macrophage Sdc-1 expression  
 Our characterizations of Sdc-1
+
 macrophages have suggested that Sdc-1 
expression is associated with both anti-inflammatory polarization states and increased 
intrinsic motility.  While expression of Sdc-1 on macrophages can be obtained in vitro 
through exposure to cAMP or adenosine, the point of control for Sdc-1 expression in vivo 
is still unknown.  Efferocytosis, a process that involves the clearance of apoptotic cells 
from the site of inflammation, has often been suggested as a physiological proresolving 
signal that can influence macrophage polarization [15, 16, 167].  Efferocytosis has also 
been suggested to result in macrophage egress from inflammatory sites [49], a process 
that is presumably associated with enhanced motility.  Moreover, efferocytosis has been 
reported to result in macrophage adenosine production [219].  Overall, these findings 
suggest that efferocytosis can potentially be involved in the regulation of macrophage 
Sdc-1 expression during inflammation.  Indeed, flow cytometry analysis demonstrated 
that macrophage exposure to apoptotic cells resulted in the upregulation of macrophage 
Sdc-1 expression (Fig.3.6), suggesting a physiologic program for expression that is 
consistent with inflammatory resolution. 
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Figure 3.6.  Efferocytosis induces macrophage Sdc-1 expression.  Sdc-1 expression was 
analyzed using flow cytometry following macrophage exposure to apoptotic cells and 
was quantified as MFI (filled: control, black line: efferocytosis; n=5). **P<0.01.  All data 














3.2.7 Sdc-1 expression on human macrophages is associated with M2 polarization and 
increased motility. 
Thus far our results have demonstrated that Sdc-1
+
 macrophages display features 
characteristic of alternatively activated M2 polarization state.  To verify Sdc-1 expression 
and to correlate our findings in murine macrophages with human macrophages, we 
decided to characterize Sdc-1 expression on human carotid plaque and polarized THP1 
derived human macrophages.  Indeed, Sdc-1 was found to be present in the human 
carotid plaque and similar to murine atherosclerotic lesion, its expression was found in 
the vicinity of macrophages (Fig.3.7A).  For our in vitro characterization, M1 
polarization on human macrophages was achieved using IFN-γ and LPS treatment, while 
Sdc-1 expression was triggered by cAMP treatment.  Surface expression of human 
leukocyte antigen-D related (HLA-DR), an MHC class II surface receptor  and a marker 
for M1 polarization [220]and Sdc-1 were analyzed by flow cytometry.  As expected, flow 
cytometry analysis indicated high expression level of HLA-DR on M1 macrophages but 
not on cAMP treated macrophages (Fig.3.8A).  On the contrary, M1 macrophages were 
found to display no Sdc-1 on their surface, while cAMP treated macrophages were found 
to upregulate their Sdc-1 expression (Fig.3.8B).  Similar to the results obtained using 
murine macrophages, macrophage Sdc-1 expression was associated with enhanced 
motility, while M1 macrophages displayed significantly dampened motility response 
(Fig.3.8C).  Overall, our findings suggest that Sdc-1 expression on both human and 
murine macrophages is associated with M2 polarization states and enhanced macrophage 






Figure 3.7.  Sdc-1 is expressed on macrophages in human carotid plaque.  Representative 
immunohistochemical staining of macrophages (CD68) and Sdc-1 in human carotid 


















Figure 3.8.  Sdc-1 expression is associated with M2 polarization state and increased 
motility in human macrophages.  A. The expression of HLA-DR and Sdc-1 was analyzed 
on THP1 derived human macrophages following exposure to M1 stimulus (IFN-γ, 
20ng/mL + LPS, 100ng/mL), or 6-benz-cAMP (100µM).  Expression was quantified as 
MFI (filled: IgG control, black line: experimental; n=3-4).  *P<0.05.  **P<0.01.  B.  
Intrinsic motility was analyzed using transwell migration to FBS.  Polarized macrophages 
were placed into the upper chamber of a transwell and macrophages that migrated to the 
lower surface of the membrane was stained, counted and reported as migration index.  





3.3  Discussion 
Macrophages are being increasingly recognized as the main player in many 
chronic inflammatory diseases. In atherosclerosis, macrophages often represent the 
dominant leukocyte population in both the early and late vascular lesion [7, 8].  While 
mechanisms regulating atherosclerosis progression have been investigated in numerous 
studies, these efforts have mainly been focused on understanding monocytes recruitment 
into the vascular wall and the proinflammatory features of the resulting macrophages.  
Numerous studies have now revealed the non homogeneous nature of macrophage 
population during inflammation.  In fact, at least four distinct macrophage polarization 
states, each with its own distinct biochemical signatures, have been identified in vitro, 
including M1, M2a, M2b and M2c [10, 13, 14, 129, 140].  Given the complexity of the 
inflammatory environment and various cytokines that are released at sites of 
inflammation, it is likely that more macrophage polarization states exist in vivo.  Our 
investigations have identified that Sdc-1, a proteoglycan that has been reported to have 
anti-inflammatory effects in several inflammation models, were expressed by 
macrophages in both murine and human atherosclerotic lesion.  Notably, this unique 
population of macrophages was found to display protective effects during atherosclerosis 
progression, which can be partly explained by their high intrinsic motility.   
Within the syndecan family, Sdc-1 is emerging as an important regulator of 
inflammatory responses.  A few studies utilizing Sdc-1-/- animals have demonstrated the 
protective effect of Sdc-1 expression during inflammation.  In a murine model of DTH 
and nephritis, the absence of Sdc-1 expression was associated with greater inflammatory 
response, prolonged inflammation, and impaired wound healing response [28, 206].  
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Recently, our group has also demonstrated that the absence of Sdc-1 resulted in the 
exacerbation of AAA formation, which was associated with increased elastin degradation 
and leukocyte infiltration [26].  Conversely, over expression of Sdc-1 can result in the 
attenuation of inflammatory responses, improved tissue healing and protection against 
cardiac dysfunction in murine model of myocardial infarction [27].  In agreement with 
these published studies, we found that Sdc-1 expression attenuated lesion formation in 
murine atherosclerosis model.  Sdc-1 expression, which co localized with macrophages, 
was found to be upregulated during atherosclerosis progression, with most Sdc-1 positive 
cells localized to the intima and adventitia region.  In contrast, little to no expression of 
Sdc-1 was detectable in the native aorta.  Importantly, the upregulation of Sdc-1 
expression and its colocalization with macrophages were also observed on human carotid 
plaque.  Given the protective effect observed in murine atherosclerosis model, Sdc-1 
expression in human macrophages may also dampen atherosclerosis progression.  
While macrophages involvement during the course of atherosclerotic progression 
is well established and has been described in numerous publications, the effects of 
macrophage polarization on lesion formation has only recently been explored [221-224].  
A study performed by Khallou-Laschet et al demonstrated a progressive shift in 
macrophage polarization during atherosclerosis progression, with M2 macrophages 
dominating early lesion and M1 macrophages dominating late, advanced lesions [202].  
Given the contrasting functions of M1 and M2 macrophages, the ratio of M1 to M2 
macrophages within atherosclerotic plaque can have a major impact in the outcome of 
inflammation.  Our in vitro characterizations indicated that Sdc-1
+
 macrophages were not 
activated to M1 polarization state, but instead displayed features characteristic of M2 
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polarized macrophages.  In fact, immunostimulated Sdc-1
+
 macrophages secreted high 
level of IL-10 that was comparable to M2c macrophages.  Importantly, Sdc-1
+
 
macrophages also displayed significantly lower leukocyte chemo-attractive potential 
compared to M1 polarized macrophages. Given that continuous leukocyte infiltration is 
one of the factors that contribute to atherosclerosis progression, Sdc-1
+
 macrophages 
presence can serve to limit leukocyte infiltration into the vascular lesion.  Our 
characterizations of Sdc-1
+
 macrophages within the atherosclerotic plaque supported the 
notion that Sdc-1 expression is associated with M2 polarization.  Immunohistochemistry 
analysis showed distinct pattern of iNOS and Sdc-1 expression within the vascular wall. 
Overall, our findings indicate that Sdc-1 expression within the atherosclerotic plaque has 
protective effects and may represent as one of the mechanisms through which resolution 
can be achieved.  
 In addition to macrophage polarization, macrophage motility is emerging as 
another factor that is crucial in determining resolution outcome [203].  Although 
macrophage is known to orchestrate inflammation, the notion that macrophage motility 
can considerably affect the outcome of inflammation has not been widely regarded 
previously.  However, the work done by Vereyken et al has demonstrated that classically 
activated M1 and alternatively activated M2a macrophage displayed distinct adhesion 
capacity and migratory behavior toward neuronal conditioned medium, with M2a 
displaying a significantly higher motility response [11].  M2a macrophages were also 
reported to display lower adhesion to extracellular matrix compared to M1 macrophages, 
which was in agreement with previous report where M1 macrophages were found to 
display increased expression of adhesion receptors [225, 226].  In addition, van Gils et al 
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has also demonstrated that dampened macrophage migration can lead to the pathogenic 
progression of atherosclerosis, which was the result of macrophage accumulation within 
the vascular wall [203].  On the contrary, increased macrophage clearance and plaque 
regression can be achieved by stimulating macrophage migration.  In agreement with 
these published studies, Sdc-1
+
 macrophages were found to display enhanced motility 
and reduced adhesion compared to M1 macrophages.  In addition, Sdc-1
-/-
 macrophages 
ware associated with dampened motility, increased adhesion and defective actin 
cytoskeletal reorganization.  Overall, our findings suggest that the protective effect 
associated with macrophage Sdc-1 expression can be partly contributed to the enhanced 
macrophage motility during inflammation. 
 Thus far our findings have pointed Sdc-1 as being expressed on macrophages that 
display anti-inflammatory characteristics and enhanced motility.  While Sdc-1 expression 
is restricted to noncirculating plasma cells and epithelial cells in adult tissue, expression 
can be induced in additional cell types, such as endothelial cells, smooth muscle cells, 
fibroblast and macrophages.  In particular, macrophage Sdc-1 expression has been 
reported to be governed via cAMP/PKA dependent post-transcriptional regulation.  
While macrophage Sdc-1 expression can be achieved in vitro through cAMP or 
adenosine exposure, the biophysical process by which macrophage Sdc-1 can be 
regulated in vivo is unknown.  Nonphlogistic clearance of apoptotic cells, or 
efferocytosis, is a key process in the regulation of macrophage M2 polarization state and 
resolution [16, 50].  Indeed, there are numerous reports detailing macrophage immune 
silencing consequent to efferocytosis [49, 99, 178, 179]; moreover, efferocytosis has been 
suggested to modulate macrophage motility and promote emigration [49].  Given our 
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findings, which correlate macrophage Sdc-1 expression with enhanced motility, we 
examined efferocytosis as an endogenous regulator of macrophage Sdc-1 expression.  
Indeed, we confirmed that macrophage exposure to apoptotic cells can result in the 
upregulation of macrophage Sdc-1 expression.  This finding further supports the notion 
that Sdc-1
+
 macrophages are anti-inflammatory and pro resolution.  
  In addition to murine atherosclerosis lesion, Sdc-1 was also found to be 
expressed in human carotid plaque.  Importantly, Sdc-1 expression appeared to colocalize 
with macrophages within the lesion site.  In vitro characterization of Sdc-1
+
 human 
macrophages confirmed Sdc-1 expression was indicative of an anti-inflammatory M2 
polarization state.  In addition, Sdc-1
+
 human macrophages also displayed enhanced 
motility compared to M1 macrophages. Overall, these observations suggest that 
macrophage Sdc-1 is potentially be involved in the regulation of inflammation in human.  
3.4 Conclusion 
In summary, in this chapter we have demonstrated that Sdc-1 expression on 
macrophages is associated with anti-inflammatory M2 polarization and enhanced motility 
in both murine and human macrophages.  Notably, efferocytosis was found to be a 
potential regulator for macrophage Sdc-1 expression in vivo.  Given that the absence of a 
sufficient anti-inflammatory and pro resolution macrophages may serve as a driving force 
in the development of chronic inflammatory disease, it is important to gain a better 
understanding of the mechanisms regulating macrophage Sdc-1 expression during 




3.5.1 Murine Model 
Both C57BL6 wild type (WT) and Apolipoprotein E (ApoE)
 -/-
 mice were 
purchased from Jackson Laboratory.  Syndecan-1 (Sdc-1)
-/-
 mice (back crossed 10 times 
onto a C57BL6 background) was kindly provided by Dr. Pyong Woo Park, (Baylor 




 (C57BL6 background) double 
knockout mice were generated by standard crossbreeding experiments.  Sdc-1
-/-
 breeder 
males were mated with ApoE
-/-
 females, and all mice were genotyped by PCR.  All 
procedures were performed in male mice according to a protocol approved by Emory 
University and Beth Israel Deaconess Medical Center Institutional Animal Care and Use 
Committee.  







, 8-12-week-old) group of mice were 
enrolled on Western high fat diet for 8 week prior to being sacrificed. 
Murine peritonitis model:  Sterile thioglycollate (TG) broth (6% w/v) was 
prepared from dehydrated TG medium (Sigma Aldrich) and sterile water.  Murine 
peritonitis was induced by intraperitoneal (IP) injection of 0.5mL of 6% sterile TG broth.   
3.5.2 Light Microscopy and Immunohistochemistry of murine atherosclerotic tissue 
 Following euthanization of animals, the heart and aorta were pressure perfused 
with 0.9% NaCl solution.  Aortic tissues was harvested and embedded in n optimal 
cutting temperature (OCT) compound (Tissue Tek), snap frozen and 5µm transverse 
cryosections prepared.  For histological analysis, sections were fixed in cold acetone and 
stained with hematoxylin and eosin.  For immunohistochemical analysis, sections were 
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fixed in cold acetone, blocked with 10% sera from the species used to generate the 
secondary antibody.  Immunocytochemical staining was performed using the following 
antibodies: boat anti Sdc-1 antibody (N-18, Santa Cruz Biotechnology) at 1:50 dilution, 
rat anti mouse macrophage antibody (Mac3, BD Biosciences) at 0.625µg/mL.  Sections 
were incubated with biotinylated secondary antibodies (Vector Laboratories) followed by 
alkaline phosphatase streptavidin (Vector Laboratories).  Negative controls with isotype 
IgG were prepared for each specimen.  Sections were then incubated with biotinylated 
secondary antibodies (Vector Labs) followed y streptavidin-alkaline phosphatase (Vector 
Labs) at 1:500 dilution.  Vector Red substrate kit 1 (Vector Labs) was used as a substrate 
for alkaline phosphatases.  At least 4 sections from each of 3 animals at each time point 
in each groups were examined.   
 Double fluorescent immunostaining was performed to confirm colocalization of 
Sdc-1 with macrophages.  Sections were first stained with anti Sdc-1 antibody (N-18, 
Santa Cruz, Biotech) at 1:50 dilution, followed by biotinylated secondary antibody and 
fluorescein conjugated streptavidin (Vector Labs) at 7.5 µg/mL.  To detect macrophages, 
the sections were then incubated with anti Mac3 antibody (BD Biosciences) at 1:50 
dilution, followed by Alexa 594 conjugated secondary antibody (Molecular Probes).  
Nuclei were visualized by 4’,6-diamidino-2-phenylindole (DAPI) staining.  At least 4 
sections from each of 3 mice at each time point from each genotype were examined.    
 Plaque iNOS was analyzed by staining with rabbit anti-mouse iNOS antibody 
(Abcam), detected by biotinylated goat anti-rabbit secondary and standard streptavidin-
HRP/Diaminobenzidine (DAB).  Quantification of iNOS positive plaque area was 
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calculated using Image Pro Plus.  At least 4 sections from each of 3 mice from each 
genotype were examined.  
3.5.3 Light Microscopy and Immunohistochemistry of human atherosclerotic tissue 
 Specimens consisting of human atherosclerotic tissue were collected at Emory 
University Hospital under an approved IRB protocol.  Specimen were fixed in 10% 
formalin overnight and then processed in a paraffin block.  5µm thick serial sections were 
analyzed with hematoxylin and eosin (Richard-Allan Scientific).  Immunocytochemical 
staining was performed to identify Sdc-1 and macrophages.  Fifteen tissue sections from 
each of five tissue samples were examined.  The following antibodies were used: 
monoclonal mouse anti human CD68 (PG-M1, Dako) at 1:100 dilution for macrophage 
identification, monoclonal Sdc-1 (DL101, Santa Cruz) at 1:100 dilution for Sdc-1 
identification.  Mouse IgG1κ (M9035, Sigma Aldrich) was used for negative control.  
The avidin-biotin complex (ABC) method was used for staining.  After deparaffinized 
and rehydrated, sections were incubated in water bath for 30 minutes at 95°C with target 
retrieval solution (S1700, Dako) for antigen retrieval.  Sections were blocked with avidin 
and biotin blocking solutions (X0590, Dako) and 10% goat serum.  The sections were 
incubated with primary antibodies for 60 minutes at room temperature, washed and 
incubated for 30 minutes with a biotinylated goat anti mouse IgG secondary antibody at 
1:1500 dilution.  After washing, the slides were incubated with streptavidin-HRP 
(KO679, Dako) for 30 minutes, then DAB substrate solution (KO679, Dako) was added 
yielded a brown product on positive cells.  Slides were counterstained with a hematoxylin 
and mounted with xylene based mounting medium (Richard-Allan Scientific). 
3.5.4 Cell culture and activation  
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 Murine peritoneal macrophages:  Mature peritoneal macrophages were isolated 
from the peritoneal exudates at 4 or 5 days following peritonitis initiation.  Peritoneal 
macrophages were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Cellgro) 
containing 10% FBS (Cellgro), 100U/mL penicillin and 100µg/ml streptomycin sulfate 
(Sigma Aldrich) at 37°C in 5% CO2 humidified incubator.  Where indicated, macrophage 
activation was induced by culturing macrophages overnight with Ifn-γ (100U/mL) and 
LPS (100ng/mL) for M1 polarization, IL-4 (20ng/mL) for M2a polarization, and IL-10 
(100ng/mL) for M2c polarization (all from R&D Systems).  Sdc-1 expression was 
induced by culturing macrophage overnight with 6-Bnz-cAMP (Sigma Aldrich, 100µM) 
or Adenosine (Sigma Aldrich, 375 µM).  Following activation period, macrophages were 
harvested using non-enzymatic cell dissociation buffer (Sigma Aldrich), washed twice 
with PBS, counted and used in further analysis/experiments as indicated.  
 Murine RAW 264.7 macrophages:  Murine RAW264.7 macrophages were 
cultured in DMEM (Cellgro) containing 10% FBS (Cellgro), 100U/mL penicillin and 
100µg/ml streptomycin sulfate (Sigma Aldrich) at 37°C in 5% CO2 humidified incubator.  
Cell culture was performed in 100x200mm tissue culture dish.  Macrophages were 
obtained by scraping and were passaged twice weekly.  For experiments, macrophages 
were obtained by scraping before being washed twice in PBS, counted and used in further 
analysis/experiments as indicated. 
 Human THP1 monocytes:  Human acute monocytic leukemia cell line was 
obtained from ATCC and cultured in suspension in Roswell Park Memorial Institute 
(RPMI) media (ATCC), supplemented with 10% FBS (ATCC) and 50nM 2-
mercaptoethanol (Sigma Aldrich).  Cell culture was performed at 2x10
5
 cells/mL in tissue 
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culture flasks and cells were passaged twice weekly when the concentration reached 
1x10
6
 cells/mL.  Monocytic differentiation was induced by incubation of 1x10
7
 cells in 
100x200mm tissue culture dish in culture media that has been supplemented with 
50ng/mL of phorbol 12-myrisate 13-acetate (PMA) (Sigma Aldrich) for 3 days.  After the 
differentiation period, M1 polarization was induced by culturing macrophages overnight 
with Ifn-γ (20ng/mL) and LPS (100ng/mL), while Sdc-1 expression was induced by 
culturing macrophage with 6-Bnz-cAMP (100µM) for 40 h.   
3.5.5 Flow cytometry 
Isolated macrophages for surface marker expression analysis were passed through 
a 70-micron cell strainer to remove debris and then counted and resuspended in FACS 
buffer (1%  bovine serum albumin (BSA) in PBS) at a concentration of 5x10
6
/mL.  
Staining was performed by combining the manufacturer’s recommended quantity of 
primary antibody to 100µL of cell suspension, followed by 30 minutes of incubation at 
4°C.  Cells were washed twice before being analyzed on the flow cytometer (LSRII, 
Becton Dickinson).  
The cell antibodies used for mouse cell staining included: anti-CD3 (145-2C11), 
anti-F4/80 (BM8), anti-I-A/I-E (M5/114.15.2), anti-CD86 (GL1), anti-CD273/PD-L2 
(TY25), anti-CD138/Sdc-1 (281-2) and anti-CD184/CXCR4 (2B11); negative controls 
with isotype IgG were included for each marker.  Anti-F4/80 and anti CD273 antibodies 
were obtained from eBioscience and the rest were obtained from BD Biosciences.  
The cell antibodies used for human cell surface markers analysis included: anti-
HLA-DR (G46-6), anti-CD163 (GHI/61), anti-CD138/Sdc-1 (MI15) and anti-
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CD184/CXCR4 (12G5); negative controls with isotype IgG were included for each 
marker.  All of the antibodies were obtained from BD Biosciences.  
 3.5.6 Nitrite Assay 
 Generation of nitrites was measured using Griess reagent kit (Invitrogen) 
according to manufacturer’s protocol.  Briefly, conditioned media were collected from 
polarized macrophages that have been cultured for 18 hours.  The nitrite level was 
measured from 150µL of filtered conditioned media (0.22µm filter) from each sample 
and it was compared to standard curve generated using standard nitrite solutions.   
3.5.7 Arginase Assay 
 Arginase activity level was determined as previously published.  Briefly, 4x10
5
 
macrophages were lysed with 80µL 0.1% Triton X-100 (Sigma Aldrich).  20 µL of Tris-
HCL and MnCl2 mixture was then added to the lysates to a final concentration of 25mM 
and 1mM respectively.  Arginase was activated by heating at 55°C for 10 minutes and 
100µL of L-arginine solution was then added to the mixture to a final concentration of 
50mM.  Mixtures were incubated at 37°C for 60 minutes and stopped with the addition of 
800µL H2SO4(96%)/H3PO4(85%)/H2O (1/3/7, v/v/v).  40µL of α-
isonitrosopropiophenone (9% solution in EtOH) was then added, followed by heating at 
100°C for 30 minutes.  Urea production was measured by measuring absorbance at 540 
nm and compared to a standard curve.  Arginase activity was compared to control 
macrophages (unstimulated peritoneal macrophages) and reported as fold change. 
3.5.8  Chemokine Profile 
For IL-10 ELISA, macrophages were first plated at 10x10
6
 cells per 100x20mm 
tissue culture dish in serum free DMEM.  Macrophage M1, M2a and M2c polarization 
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and macrophage Sdc-1 expession (Ado) was induced as described above with the 
addition of LPS at 100ng/mL.  With the exception of M2c polarization, conditioned 
media was collected after 24 hours.  For M2c polarization, macrophages were cultured in 
the presence of the stimulus and LPS for 24 hours.  After the initial stimulation, serum 
free DMEM was added and conditioned media was collected after an additional 24 hours 
of culture.  Collected media was filtered (0.22µm) and subjected to 8-fold concentration 
(Amicon Ultra, 3000 NMWL) and analyzed using an IL-10 ELISA kit (SA Biosciences). 
3.5.9 Phagocytosis Index 
Peritoneal macrophages were cultured in a 6 well cell culture plate (2x10
6
/well) 
and macrophage polarization was induced as described above.  % phagocytosis was 
determined by incubating macrophages with fluorescently labeled microspheres (1µm 
diameter, Polysciences) at a ratio of 1:15 for 2 hours at 37°C in 5% CO2 humidified 
incubator.  Excess microspheres were removed by washing 3x with PBS and 
macrophages were then harvested using non-enzymatic cell dissociation buffer (Sigma 
Aldrich) and washed.  Percent phagocytosis was obtained by analyzing the macrophages 
using flow cytometry.  
3.5.10 PCR Array 
mRNA expression analysis of 84 genes that encode chemokines and their 
receptors were performed using mouse chemokines and receptors RT2 profiler PCR array 
(SABiosciences).  RNA was extracted from classically activated M1 and Sdc-1
+
 
(Adenosine) macrophages with TRIzol reagent (Invitrogen) and purified using RNeasy 
mini kit (Qiagen) according to manufacturer’s protocol.  A total of 1µg of RNA from 
each sample were converted to cDNA using the RT
2
 first strand kits (SABiosciences) and 
 71 
was then subjected to PCR array analysis on the Applied Biosystems 7900 using the RT
2
 
qPCR Master Mixes according to manufacturer’s protocol (SABiosciences).  Data were 
analyzed using the web-base PCR array data analysis tool from SABiosciences.  mRNA 
expression level for each gene was normalized to  the expression level of 
glyceraldehydes-3-phosphage dehydrogenase (GAPDH) using the equation 2
-(Ct[gene of 
interest]-Ct[GAPDH])
, where Ct is the threshold cycle.  Normalized gene expression levels of 
experimental samples (Sdc-1
+
 macrophages) were obtained by comparing the gene 
expression level to control samples (M1 macrophages).  Each reported value represents 
the mean fold increase or fold decrease of mRNA expression in experimental samples 
relative to controls.   
3.5.11 Leukocyte Chemotaxis 
 Peripheral mouse blood monocytes were obtained by negative selection using the 
Mouse Monocytes Enrichment Kit (StemCell Technologies) according to manufacturer’s 
instruction.  Briefly, mouse blood was obtained through cardiac puncture and was 
collected in syringes and tubes coated with sodium citrate. Leukocytes were obtained 
following red blood cell (RBC) lysis using RBC Lysis Buffer (eBioscience) and PBS 
wash.   Mouse monocytes were obtained from the cell suspension using the Mouse 
Monocytes Enrichment Kit (StemCell Technologies) according to manufacturer’s 
instruction. 
 CD4+ T cells were negatively selected from splenocytes (Miltenyi Biotech) 
according to manufacturer’s protocol.  Enriched T cells were cultured in DMEM 
supplemented with 10% FBS, IL-2 (10ng/mL, R&D Systems), IL-12 (20ng/mL, R&D 
Systems) to produce the desired Th1 polarized response, while Dynabeads Mouse T-
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Activator CD3/CD28 (Invitrogen) was utilized for the activation and expansion of the T 
cells according to manufacturer’s protocol.   
Chemotaxis assays were performed by loading 100 µL of T cells or monocytes 
that have been resuspended at a concentration of 1x10
5
cells/mL in DMEM containing 
0.5% FBS, onto the upper well of a 24-well transwell permeable supports with a pore size 
of 5µm (Corning).  Conditioned media obtained (600µL) from polarized macrophages 
that have been cultured for 18 h in DMEM containing 0.5% FBS was added to the lower 
well.  The migration response was quantified after 4 hours of incubation at 37°C in 5% 
CO2 humidified incubator and was reported as % migrated.  
3.5.12 Macrophage Migration Assay 
Intrinsic motility of macrophages was analyzed by loading 100 µL of peritoneal 
macrophages that have been resuspended at a concentration of 1x10
6
/mL in DMEM 
containing 0.5% FBS onto the upper well of a 24-well transwell permeable supports with 
a pore size of 8µm (Corning).  In experimental group, DMEM containing 10% FBS was 
added onto the lower well, and macrophages were then incubated at 37°C in 5% CO2 
humidified incubator; DMEM containing 0.5% FBS was used in the control group.  In 
order to analyze the intrinsic motility of polarized macrophages, M1, M2a, M2c or cAMP 
was added onto both upper and lower chambers.  After 18 hours of incubation, 
macrophages that have migrated onto the lower well surface of the membrane were fixed 
with 10% formalin in PBS for 10 minutes.  Macrophages that adhere to the upper well 
were scraped and the membrane was then stained with hematoxylin (Sigma Aldrich).  For 
each replicate, peritoneal macrophages were obtained from separate mice and 3 separate 
wells were included.  The numbers of macrophages in three independent fields of view 
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were counted in each well and averaged.  Migration was quantified as migration index by 
dividing the number of macrophages counted in experimental compared to control group.  
Intrinsic motility of human THP1 derived macrophages was investigated in a 
similar manner as described above.  However, only the effect of M1 stimulus and cAMP 
on macrophage migration response was analyzed.  
3.5.13 Adhesion Assay 
Macrophage adhesion to fibronectin was determined using macrophages that have 
been activated with M1 stimulus or 6-Bnz-cAMP and were labeled with 1.5µM CellTrace 
crboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) according to manufacturer’s 
protocol.  Following fluorescent labeling, cells were harvested, washed and seeded 
(1x10
5 
in 100µL) in 96 wells cell plate that has been coated with fibronectin (5µg/cm
2
).  
Macrophages were then cultured for 2 hours at 37°C in 5% CO2 humidified incubator.  
Non-adherent macrophages were removed by washing 3 times with PBS and adherent 
macrophages were then lysed with 100µL of 0.1M NaOH.  Fluorescence signal was 
measured using a fluorescence plate reader.  Cell number was obtained using a standard 
curve generated with known concentration of fluorescently labeled macrophages. 





 macrophages were fixed with fixed with 10% 
formalin in PBS for 10 minutes and permeabilized with PBS containing 0.5% Triton X-
100 (Sigma Aldrich), rinsed with 100mM glycine (Sigma Aldrich), and incubated with 
block buffer (0.2% TrionX-100 and 6% goat serum in PBS).  Cells were then stained 
with Alexa Fluor568 conjugated Phalloidin (Invitrogen).  Nuclei were counterstained 
with DAPI (Invitrogen) prior to being evaluated with confocal microscopy.   
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3.5.15 Generation of Apoptotic Cells and Efferocytosis Experiment 
Apoptotic RAW 264.7 cells macrophages were generated by exposure of plated 
macrophages to ultraviolet (UV) light.  Macrophages were plated at 10X10
6
 cells per 
100x20mm tissue culture dish and were then placed 5 inches from the UV (254nm) 
source and exposed to UV light for 5 minutes with the culture dish lid off in a cell culture 
hood.  Irradiated macrophages were then cultured at 37°C in 5% CO2 humidified 
incubator for 2 hours.  Apoptotic macrophages were then harvested using non-enzymatic 
cell dissociation buffer (Sigma Aldrich), washed using PBS prior to being used. 
Efferocytosis experiment was performed by adding apoptotic macrophages to 
cultured peritoneal macrophages (15 to 1 ratio)  in DMEM supplemented with 0.5% FBS, 
which were then placed at 37°C in 5% CO2 humidified incubator.  Following 2 hours of 
incubation, excess apoptotic cells were removed by washing with PBS and remaining 
macrophages were cultured for additional 40 hours.  Macrophages were removed using 
harvested using non-enzymatic cell dissociation buffer (Sigma Aldrich) and washed using 
PBS prior to being stained for flow cytometry analysis.   
3.5.16 Statistical Analysis 
 Means and SEM were calculated for each parameter.  All data were analyzed via 
2-tailed Student t test.  For the PCR array analysis, the P values were calculated based on 
a Student t test of the replicate 2
-(Ct[gene of interest]-Ct[GAPDH]) 
values for each gene in both the 
control and experimental groups.  Values of P<0.05 were considered statistically 





SYNDECAN-1 PARTICIPATES IN MACROPHAGE EGRESS 
TOWARD THE LYMPHATIC NETWORK 
 
Our findings have established that Sdc-1 expression on macrophages is indicative 
of an anti-inflammatory polarization state and that its presence during inflammation can 
dampen pathogenic disease progression.  Our characterizations suggest that in addition to 
the anti-inflammatory macrophage polarization state, the observed protective effect can 
also be potentially explained by enhanced macrophage migration associated with Sdc-1 
expression.   In fact, one of the key features that define resolution of inflammation is the 
effective egress of macrophages out of the inflammatory site to the draining lymphatic 
network.  Given our findings, we postulate that the increased motility response observed 
in Sdc-1
+
 macrophages can contribute to increased macrophage egress from inflammation 
site, which results in dampened inflammatory responses and resolution of inflammation.  
4.1 Introduction 
One of the defining features of chronic inflammation is the persistence of 
activated macrophages at the site of inflammation.  While numerous studies have 
confirmed that continuous leukocyte influx can contribute to the development of chronic 
inflammation, failure of macrophages to egress from the site of inflammation to the 
draining lymphatics is another factor that has been shown to participate in the process [7, 
16, 41].  This delayed macrophage clearance can result in the accumulation of activated 
macrophages, which results in the maintenance of proinflammatory environment within 
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the inflammation site.  This, in turn, can result in the additional recruitment of monocytes 
that mature into proinflammatory macrophages within the tissue.  Overall, delayed 
macrophage clearance can result in the generation of a proinflammatory feedback loop 
that fuels the development of chronic inflammation.  
Studies utilizing various murine inflammation models, including atherosclerosis, 
lung inflammation and peritonitis have demonstrated that macrophages can exit 
inflammation site via nearby draining lymphatics during inflammation [51, 99, 128, 198, 
227].  Importantly, egress toward the lymphatics was associated with inflammation 
resolution [49, 99, 198].  In murine model of atherosclerosis regression, surgical 
transplantation followed by aggressive lowering of cholesterol level resulted in 
macrophage clearance to the nearby draining lymph nodes, which was associated with 
significant decrease in atherosclerotic plaque size [198].  A similar process involving 
macrophage migration toward the lymphatics has also been noted in the resolution of 
peritonitis, where macrophages were observed to egress from the peritoneal cavity toward 
the draining lymph nodes [51, 99].  In addition, macrophage efferocytosis was found to 
accelerate macrophage clearance toward the draining lymphatics [99].  Overall, these 
reports indicate that macrophage egress into the draining lymph nodes is correlated with 
inflammatory resolution. 
In the previous chapter, we have established that Sdc-1 expression on 
macrophages is associated not only with anti-inflammatory polarization state, but also 
with enhanced motility response.  In addition, absence of Sdc-1 expression within the 
atherosclerotic plaque was associated with accelerated plaque growth.  Thus, we 
hypothesized that the enhanced macrophage motility associated with Sdc-1 expression 
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can contribute to macrophage egress from the site of inflammation and thus limit the 
progression of inflammation.  In fact, the link between macrophage Sdc-1 expression and 
migration toward the lymphatic has been suggested previously [29], though it was not 
confirmed.  
In this chapter, we establish that the enhanced motility associated with Sdc-1 
expression is indeed associated with macrophage egress from the inflammation site 
toward the draining lymphatics.  Characterization of macrophage influx and efflux from 




 mice revealed that the 
absence of Sdc-1 expression resulted in the accumulation of macrophages within the 





macrophages into the peritoneal cavity of mice 
undergoing peritonitis confirmed that Sdc-1 absence resulted in decreased macrophage 
egress toward the draining lymphatic.  Thus, our data suggest that the protective effects 
associated with Sdc-1 expression can be attributed to enhanced macrophage egress, 
which supports the resolution of inflammation 
4.2  Results  
4.2.1 Sdc-1 is expressed on macrophage during the course of peritonitis response  
The potential involvement of Sdc-1 in macrophage clearance during inflammation 
was investigated using a murine model of peritonitis, a self resolving model of acute 
inflammation that is commonly used to study leukocyte clearance to the draining lymph 
nodes.  In order to determine Sdc-1 involvement during peritonitis, flow cytometry was 
used to characterize Sdc-1 expression in concert with macrophage infiltrate over the 12 
day time course of TG induced murine peritonitis.  Flow cytometry analysis confirmed 
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that Sdc-1 was expressed on macrophages during the 12 day time course of peritonitis.  
The number of Sdc-1
+
 macrophages increased and peaked 2 days after the peritonitis 
induction, and decreased thereafter (Fig.4.1A), while little to no expression of Sdc-1 was 
detected on resident peritoneal macrophages.  It is worth noting that not all of the 
macrophages express Sdc-1, which highlighted the non homogeneous nature of the 
macrophages present in the peritoneal cavity during peritonitis (Fig.4.1B).  In light of our 
in vitro characterization of Sdc-1
+
 macrophages, which showed the relationship between 





 macrophages during the peritonitis response.  We observed that early during the 
peritonitis response (12hr), only a small portion of the macrophages are expressing Sdc-1 





was not significantly different, though both increased and peaked at day 2.  Significantly, 
the decline in the total macrophage population thereafter was associated with a dominant 
loss of Sdc-1
+
 compared to Sdc-1
-
 macrophages (Fig.4.2A).  Overall, our findings 
confirm the involvement of macrophage Sdc-1 in the regulation of murine TG induce 
peritonitis model.   
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Figure 4.1.  Macrophage Sdc-1 expression during the course of peritonitis.  A.  
Macrophages response was analyzed at various time points post thioglycollate injection.  
B. Macrophage response in conjunction with Sdc-1 expression was analyzed  at various 
time points.  % of Sdc-1 expressing macrophages compared to total macrophages was 
analyzed at various time points during peritonitis response (n=3, 5, 5, 3, 3, 4, 3, 8 at 0, 12 

















Figure 4.2.  Macrophage Sdc-1 expression during the course of peritonitis.  Macrophage 
response in conjunction with Sdc-1 expression was analyzed at various time points post 
thioglycollate injection (n=3, 5, 5, 3, 3, 4, 3, 8,and 4 at 0, 12 hours (h), 18h, 1day (d), 2d, 













4.2.2  The absence of Sdc-1 expression is associated with macrophage accumulation 
within the peritoneal cavity  
To further study the functional significance of Sdc-1 in macrophage egress during 




 mice in the TG induced peritonitis 
model and compared the leukocyte influx and efflux profile.  Cells were harvested by 
lavage over the 12 day time course model, total cell counts were recorded and flow 
cytometry was utilized to identify neutrophils and macrophage populations.  While 
analysis of total cell counts revealed no difference in the kinetics of inflammatory influx 
and the magnitude of the peritonitis response, as noted in the peak of the response at day 
2, we did observe a significant difference at later time points, with greater cell numbers 
observed in Sdc-1
-/-
 mice (Fig.4.3A).  In addition, we also analyzed the percent 
neutrophils and percent macrophages at each time point.  The evolution and resolution of 
the neutrophil response was characteristic of a self resolving peritonitis model with no 




 mice (Fig.4.3B).  Looking at the 




 mice.  
However, we did record a significant difference in the resolution of the macrophage 
response, with greater number of macrophages remaining in the peritoneal cavity of Sdc-
1
-/-
 mice (Fig.4.3C,D).  Thus, similar to our previous in vitro characterization, our 
findings from the peritonitis model suggest that Sdc-1 expression may be an important 







Figure 4.3.  Leukocyte response during the course of peritonitis.  A-C. Leukocytes 
response was analyzed in thioglycollate induced peritonitis in in Sdc-1
+/+
 (WT) and Sdc-
1
-/- 
(KO) mice.  A.  Total peritoneal cells, B. neutrophils, and C. macrophages response 
was analyzed at various time points post thioglycollate injection.  D. % increase of KO
 
compared to WT macrophages that remain in peritoneal cavity at 5,8,10 and 12 days post 
thioglycollate injection (n=3, 5, 5, 3, 3, 4, 3, 8 and 4 at 0, 12 hours (h), 18h, 1day (d), 2d, 
5d, 8d and 10d respectively).  All data represent the mean ± SEM. 
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4.2.3 Sdc-1 expression is involved in macrophage egress toward the draining lymph 
nodes during inflammation resolution 
 One of the hallmarks of chronic inflammatory diseases is macrophage failure to 
egress from the inflammation site to the draining lymph nodes.  As described above, the 
absence of Sdc-1 expression was found to result in macrophage accumulation within the 
peritoneal cavity.  In addition, we have also demonstrated that Sdc-1 absence was 
associated with increased atherosclerotic lesion formation (Chapter 3).  Given the 
association between the lack of Sdc-1 expression and reduced macrophage intrinsic 
motility, it is probable that the delayed macrophage clearance observed in Sdc-1
-/-
 mice is 
related to dampened macrophage egress toward the draining lymph nodes.  To investigate 
this question, we utilized an adoptive transfer model in which fluorescently labeled 
macrophages were transferred into the peritoneal cavity of mice undergoing the same 
stage of peritonitis.  In order to verify Sdc-1 involvement in macrophage clearance to the 




 macrophages were fluorescently labeled with 
CellTrace carboxyfluorescein diacetate succinimidyl (CFSE)  and CellTrace Violet 
respectively, and mixed at a ratio of 1:1.  The fluorescently labeled mixed macrophage 
population was then adoptively transferred into the peritoneal cavity of Sdc-1
+/+
 mice 
undergoing peritonitis at the same stage.  Mesenteric lymph nodes and spleen were 
collected following 18 hours of incubation period.  Leukocyte suspension obtained from 
processed tissue was analyzed using flow cytometry analysis to check for the presence of 
adoptively transferred labeled macrophages. Consistent with our in vitro finding that Sdc-
1 absence resulted in decreased intrinsic motility, deficiency in macrophage Sdc-1 
expression resulted in dampened macrophage egress toward the draining lymphatic.  
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Flow cytometry analysis of fluorescently labeled macrophages recovered from processed 
tissue showed higher percentage of Sdc-1
+/+
 macrophages compared to Sdc-1
-/-
 
macrophages in both the mesenteric lymph nodes and spleen (Fig.4.4).  These findings 
suggest that dampened macrophage intrinsic motility observed in vitro in the absence of 
Sdc-1 expression can translate to reduced macrophage motility and egress in vivo.  In 
addition, these results reinforce the significance of macrophage motility as a regulator of 



















Figure 4.4.  Absence of Sdc-1 expression is associated with delayed macrophage 
clearance to the lymphatics.  Fluorescently labeled Sdc-1
+/+
 (WT) and Sdc-1
-/- 
(KO) 
macrophages (1:1 mixture) were adoptively transferred into the peritoneal cavity of WT 
mice undergoing the same stage of peritonitis (day 3 post peritonitis induction).  Mice 
were sacrificed at 18 hours post adoptive transfer and the mesenteric lymph nodes and 
spleen were harvested and processed.  Cells obtained from the tissues were analyzed to 
determine the percentage of WT and KO macrophages from fluorescently labeled cells 




Macrophage egress is understood to be crucial for the effective resolution of 
inflammation and numerous recent publications have attempted to uncover the stimulus, 
receptors, signaling pathways and other points of control that are involved in this process 
[41, 49, 51, 90, 99, 128, 198, 199, 203].  While progress has been made in understanding 
the regulation of macrophage clearance, many of the mechanisms involved are still 
poorly understood.  In this chapter, we report that the absence of macrophage Sdc-1 
expression does not affect macrophage influx within the peritoneal cavity during 
peritonitis.  Instead, Sdc-1 was found to be involved in the egress of macrophages from 
the peritoneal cavity into the local draining lymphatic.  Thus, macrophage Sdc-1 
expression during inflammatory response may serve to limit the scope of inflammation 
through active macrophage clearance out of the inflamed tissue.   
As we have demonstrated in the previous chapter, the absence of Sdc-1 
expression on macrophages was associated with dampened motility and exaggerated 
atherosclerosis progression.  While macrophage egress to the lymphatic has been 
previously studied using murine model of atherosclerosis, it involved robust lipoprotein 
profile change achieved through surgical transplantation of atherosclerotic arterial 
segment or ApoE gene complementation using adenoviral vectors [41, 198].  In an 
attempt to investigate the mechanism by which increased macrophage motility can lead to 
protective effect during inflammation, we investigated macrophage infiltration and 
emigration in a murine peritonitis model.  In agreement with our previous finding in 
which macrophage Sdc-1 expression was found to be upregulated in response to 
efferocytosis, we observed an upregulation of macrophage Sdc-1 expression that 
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coincided with neutrophils infiltration and clearance.  Unlike macrophages, neutrophils 
quickly turn apoptotic following extravasation to the inflammation site and are 
subsequently cleared by infiltrating macrophages through efferocytosis.  We observed 
that the neutrophil count was significantly upregulated at 12 hours and reached a 
maximum at 18 hours post TG injection.  Accordingly, the number of Sdc-1
+
 macrophage 
within the peritoneal cavity increased significantly during this time frame.  Thereafter, 
the number of neutrophils started to decrease, with the majority of neutrophils being 
cleared 2 days post TG injection.  At the same time, the number of Sdc-1
+
 macrophages 
continued to increase within this time frame.  Interestingly, the number of Sdc-1
+
 
macrophages started to decrease following neutrophils absence in the peritoneal cavity.  
Thus, it is likely that macrophage Sdc-1 expression during peritonitis was associated with 
macrophage efferocytosis of apoptotic neutrophils.  In addition, it is important to note 
that the early decline in total macrophage count from the peritoneal cavity was largely 
associated with the loss of macrophages that express Sdc-1.  Decrease in the number Sdc-
1
-
 macrophages was noted only following the clearance of the majority of Sdc-1
+
 
macrophages from the peritoneal cavity.  Overall, our data support our previous finding, 
which linked macrophage Sdc-1 expression with efferocytosis and enhanced motility.  
Our in vivo data support the notion that Sdc-1 expression is involved in 
macrophage clearance during inflammation.  Indeed, further characterization utilizing 
Sdc-1
-/-
 mice confirmed that while the total macrophage influx was similar to Sdc-1
+/+
 
mice, the absence of Sdc-1 expression was associated with delayed macrophage clearance 
out of the peritoneal site.  While the reduction that we observed was modest, the 
difference recorded was statistically significant.  In addition, given the acute nature of 
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peritonitis model, it is possible that under a stronger inflammatory challenge, a more 
profound difference in macrophage clearance can be obtained.  Nevertheless, in vivo 




 mixed macrophage 
population confirmed that Sdc-1 absence resulted in significantly decreased egress 
toward the draining lymph node and spleen.  Thus, delayed macrophage clearance from 
the peritoneal cavity in the absence of Sdc-1 expression can be correlated with dampened 
macrophage egress toward the lymphatic system.  This suggests that macrophage Sdc-1 
expression is potentially a part of the mechanisms that is involved in the regulation of 
inflammation resolution.   
4.4 Conclusion 
In summary, in this chapter we have demonstrated that Sdc-1 expression was 
involved in macrophage clearance from the site of inflammation.  Notably, Sdc-1 
expression was also associated with enhanced macrophage egress toward the draining 
lymph nodes.  Overall, these findings reinforce the physiological significance of 
macrophage Sdc-1 expression during inflammatory response and their involvement in the 







4.5.1 Murine Peritonitis Model 
C57BL6 wild type (WT) mice were purchased from Jackson Laboratory.  
Syndecan-1 (Sdc-1)
-/-
 mice (back crossed 10 times onto a C57BL6 background) was 
kindly provided by Dr. Pyong Woo Park, (Baylor College of Medicine, Houston, TX).  
All procedures were performed in male mice according to a protocol approved by Emory 
University and Beth Israel Deaconess Medical Center Institutional Animal Care and Use 
Committee.  
Sterile TG broth (6% w/v) was prepared from dehydrated TG medium (Sigma 
Aldrich) and sterile water.  Murine peritonitis was induced by IP injection of 0.5mL of 
6% sterile TG broth.  For characterization of peritonitis response, peritoneal exudates 
were collected at 12 hours, 18 hours, 1 day, 2 days, 5 days, 8 days, 10 days, and 12 days 
following peritonitis induction.  Peritoneal leukocytes were obtained through lavage 
using 5mL of sterile PBS with 1mM EDTA.  The expression of Sdc-1 and the number of 
macrophages, neutrophils, and T cells in the peritoneal lavage was determined by 
performing total cell count and analyzing the percentages of each cell types using flow 
cytometry analysis. 
4.5.2 Flow cytometry 
Isolated macrophages for surface marker expression analysis were passed through 
a 70-micron cell strainer to remove debris and then counted and resuspended in FACS 
buffer (1%  BSA in PBS) at a concentration of 5x10
6
/mL.  Staining was performed by 
combining the manufacturer’s recommended quantity of primary antibody to 100µL of 
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cell suspension, followed by 30 minutes of incubation at 4°C.  Cells were washed twice 
before being analyzed on the flow cytometer (LSRII, Becton Dickinson).  
The cell antibodies used mouse cell staining included: anti-Gr1 (RB6-8C5), anti-
CD3 (145-2C11), anti-F4/80 (BM8), and anti-CD138/Sdc-1 (281-2); negative controls 
with isotype IgG were included for each marker.  Anti-F4/80 antibodies were obtained 
from eBioscience and the rest were obtained from BD Biosciences.  
4.5.3 Adoptive Transfer 
For adoptive cell transfer experiments, peritonitis was induced in both WT and 
Sdc-1
-/- 
donor mice and WT recipient mice 3 days prior to adoptive transfer.  WT 
macrophages were labeled with 3µM CellTace CFSE (Invitrogen) while Sdc-1
-/-
 
macrophages were labeled with 5 µM CellTrace Violet (Invitrogen) according to 
manufacturer’s protocol.  WT and Sdc-1
-/- 
macrophages were then counted and mixed 
(1:1 ratio) at a final concentration of 1x10
6
cells/mL in sterile PBS.  Mixed cell 
suspension was then injected into the peritoneal cavity of WT recipient mice (1mL/mice) 
that were undergoing the same stage of peritonitis as the donor mice.  Recipient mice 
were sacrificed 18 hours post adoptive transfer and the mesenteric lymph nodes and 
spleen were harvested and processed for flow cytometry analysis. Lymph node was 
processed by mechanical disruption.  Lymph nodes were first gently disaggregated with 
the tip of 18G needles in a small petri dish with DMEM supplemented with 5% FBS,  
before being further processed by pressing against the bottom of the petri dish with the 
plunger of a 6 mL syringe in a circular motion until mostly fibrous tissue remains.   
Tissue clumps were further dispersed by drawing up and expelling several time using 6 
mL syringe and an 18G needle.  Cell suspension and additional wash from the petri dish 
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were filtered (100µm) and washed.  Harvested spleen was processed by mechanical 
disruption between two microscope glass slides in a petri dish with PBS.  Cell suspension 
was obtained following filtration (100µm) and RBC lysis using RBC Lysis Buffer 
(eBioscience) and PBS wash.  Fluorescently labeled cells were analyzed and presence of 
CFSE and Violet dye were reported at %WT or %Sdc-1
-/-
 macrophages respectively.  
4.5.4 Statistical Analysis 
 Means and SEM were calculated for each parameter.  All data were analyzed via 





EFFEROCYTOSIS AS A REGULATOR OF MACROPHAGE CXCR4 
EXPRESSION AND EGRESS IN INFLAMMATION 
 
Some key features that characterize the resolution of inflammation are the 
effective clearance of apoptotic cells and the successful emigration of macrophages out of 
the inflammatory site to the draining lymphatic network.  While the mechanisms by 
which monocytes are recruited into the inflammatory site is well understood, not as much 
is known regarding the regulation of macrophage motility within the inflammatory site 
itself and how macrophages are cleared at the end of inflammatory response.  Given 
macrophage prevalence in chronic inflammatory disease and the importance of its 
clearance in order to achieve resolution, it is important to understand the mechanisms by 
which macrophage motility can be regulated during inflammatory responses.   
5.1 Introduction 
 Similar to other immune cells, macrophage migration is governed through the 
expression of chemokines and chemokine receptors.  However, unlike other immune 
cells, chemokine receptor expression pattern on macrophages is not as well described and 
understood.  Recent studies that have highlighted the complexities of macrophage 
polarization states have served as an indication that the regulation of macrophage 
chemokine receptors is likely to be just as complex. Just as each macrophage polarization 
state can be associated with its own unique biochemical signature and functional activity, 
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it is highly likely that each polarization state is also associated with distinct motility 
behavior and unique chemokine receptor expression profile. 
 We, and others, have noted that the intrinsic motility of M1 macrophages is 
greatly reduced when compared to their M2 counterparts. The work done by Vereyken et 
al has demonstrated that classically activated M1 and alternatively activated M2a 
macrophages display distinct adhesion capacity and migratory behavior toward neuronal 
conditioned medium [11].  They reported M1 and M2a macrophages migratee distinctly 
toward conditioned media obtained from cultured central nervous system cells, with M2a 
macrophages displaying a significantly higher motility response.  M2a macrophages were 
also reported to display lower adhesion to extracellular matrix compared to M1 
macrophages.  This was in agreement with previous studies where macrophage exposure 
to M1 stimulus resulted in increased expression of adhesion receptors [225, 226].  
Overall, the M2a phenotype was associated with macrophages that displayed lower 
adhesion and higher motility, which the authors postulated made the macrophages more 
prone to migrate toward neurons during inflammation, where they can exert their anti-
inflammatory and tissue healing effect.  
 Despite these marked differences in motility potential, chemokine receptor 
expression pattern in relation to macrophage polarization state has not been thoroughly 
investigated.  CCR7 has previously been suggested as a candidate chemokine receptor 
mediating macrophage clearance out of inflamed tissue [198, 199].  In an animal model 
of atherosclerosis in which plaque regression and macrophage clearance was observed 
following transplantation of plaque containing arterial segments from ApoE
-/- 
to wild type 
mice, in vivo blockade of CCR7 function by injection of antibodies that bind to CCR7 
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ligands, resulted in the abrogation of pro resolution responses that were previously 
observed [198].  However, in a more recent study that was performed using an 
atherosclerosis model system that did not involve surgery, in which atherosclerosis was 
reversed with ApoE encoding adenoviral vectors, CCR7 was found not to be involved in 
the lowering of macrophage content within the atherosclerosis plaque [41].  In fact, 
macrophage CCR7 expression has actually been link to the more sessile, 
proinflammatory M1 subtype [129, 200].  This warrants a more systemic examination of 
motility potential and chemokine receptor expression in M2 macrophages and how they 
are regulated during inflammation.  
 In this chapter, we demonstrate that M1 and M2 macrophages are associated with 
distinct chemokine receptor expression.  We report that M2 macrophages display high 
expression level of CXCR4, CX3CR1 and CCR10 compared to M1 macrophages.  The 
expression level of CCR7 was found to be higher in M1 macrophages, as previously 
reported [129, 200].  Notably, efferocytosis, a process that has been characterized as the 
physiological pro resolution switch for macrophages, was found to upregulate CXCR4 
expression in both human and murine macrophages in vitro.  Enhanced expression of 
CXCR4 during murine model of peritonitis was found to participate in macrophage 
clearance from the peritoneal cavity to the draining lymphatic system.  In addition, 
macrophages expressing high level of CXCR4 were also found to express higher level of 
Sdc-1 on their surface.  Thus, our data suggest that efferocytosis driven CXCR4 
expression can participate in the regulation of macrophage motility within inflammation 
site and potentially affect the dynamic and outcome of many inflammatory diseases. 
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5.2  Results  
5.2.1 Characterization of chemokine receptor expression in M1 and M2 macrophages 
 As discussed in the previous chapter, our characterizations of Sdc-1
+
 
macrophages have indicated that these macrophages display characteristics that are 
associated with M2 polarization.  In order to perform a more systemic examination of 
chemokine receptor expression in polarized macrophages, the gene expression profile of 
chemokine receptors in M2/Sdc-1
+
 and M1 macrophages were investigated using the 
chemokines and receptors RT2 profiler PCR array.  RNA was extracted from M1 
macrophages and M2/Sdc-1
+
 macrophages, which were obtained following macrophage 
exposure to LPS and IFN-γ, or macrophage exposure to adenosine and enrichment using 
the MACS system, respectively.  Analysis of the chemokine receptor expression levels in 
these macrophages, which were normalized to GAPDH expression level, revealed that 
CXCR4, CX3CR1 and CCR10 were expressed at a significantly higher level in M2/Sdc-
1
+
 compared to M1 macrophages (Table 5.1).  We utilized a transwell chemotaxis 
experimental setup to determine if these chemokine receptors were expressed on 
macrophage surface and if they were functionally active.  In addition, the effect of 
macrophage polarization on chemotaxis response was also examined.  In this experiment, 
1x10
5
 of macrophages were added to the upper chamber transwell plates with 5 µm pore 
size following exposure to M1 or M2 stimulus, while corresponding ligands were added 
to the bottom chamber.  Using this setup, we found that M2/Sdc-1
+
 macrophages 
displayed higher chemotaxis response toward each of the corresponding ligands 
compared to M1 macrophages (Fig. 5.1).  This agrees with our previous finding where 
M2 macrophages were found to display higher intrinsic motility compared to M1 
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macrophages.  We have also previously demonstrated that the absence of Sdc-1 
expression was associated with reduced motility (Chapter 3).  Thus, the experiment was 
repeated using Sdc-1
-/-
 macrophages to investigate Sdc-1 involvement in macrophage 
chemotaxis. As expected, significantly reduced chemotaxis response was observed in the 
absence of Sdc-1 expression when macrophages were exposed to adenosine (Fig 5.2A), 
while low chemotaxis response was observed in both groups when macrophages were 











Table 5.1 mRNA expression profile of chemokine receptors in Sdc-1
+
 compared to M1 
macrophages. RNA was extracted from Sdc-1
+
 or M1 macrophages and analyzed on the 
chemokines and receptors RT1 profiler PCR array; expression were normalized to GAPDH 




:M1 Ligand Gene Information 
CXCR4 48 CXCL12/SDF-1 Co-receptor used by HIV virus to infect 
macrophages 
CCR10 12 CCL27 Participate in the regulation of skin 
inflammation 
CX3CR1 12 CX3CL1 Participate in the recruitment of monocyte 
into the inflammatory site 
CCR7 -31 CCL19, CCL21 Participate in lymph node homing and is 





Figure 5.1.  Chemotaxis response of M1 and Sdc-1
+
 macrophages.  M1 or Sdc-1
+
 
macrophages were placed in the upper chamber of a transwell while select ligands were 
placed in the lower chamber (CXCL12, 200ng/mL; CX3CL1, 400ng/mL; CCL27, 
250ng/mL).  After 18h, macrophages that have migrated to the lower surface of the 
chamber were stained using hematoxylin, counted and reported as migration index (n=4).  
*P<0.05.  **P<0.01.  All data represent the mean ± SEM. 
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Figure 5.2.  Absence of Syndecan-1 expression is associated with reduced chemotaxis 
response.  A-B.  Sdc-1
+/+
 (WT) and Sdc-1
-/- 
(KO) macrophages were placed in the upper 
chamber of a transwell while select ligands were placed in the lower chamber (CXCL12, 
200ng/mL; CX3CL1, 400ng/mL; CCL27, 250ng/mL).  After 18h, macrophages that have 
migrated to the lower surface of the chamber were stained using hematoxylin, counted 
and reported as migration index.  A.  Chemotaxis response of macrophages under M1 
polarization was analyzed (n=4).  *P<0.05.  B.  Chemotaxis response of macrophages 
under Ado treatment was analyzed (n=4).  All data represent the mean ± SEM. 
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5.2.2 Efferocytosis as a regulator of macrophage chemokine receptor expression 
Our characterizations of M1 and M2/Sdc-1
+
 macrophages have suggested that 
macrophage polarization can affect both macrophage motility and chemotaxis response.  
In particular, certain chemokine receptors including CXCR4, CX3CR1 and CCR10 were 
upregulated only on M2/Sdc-1
+
, but not M1 polarized macrophages.  While these 
receptors can be expressed in vitro following macrophage treatment with adenosine, how 
their expression is regulated in vivo is unclear.  As we have previously demonstrated, 
efferocytosis can regulate the expression of macrophage Sdc-1.  Thus, we elected to 
investigate the potential of efferocytosis in regulating macrophage chemokine receptor 
expression.  We investigated the ability of apoptotic macrophages to stimulate 
macrophage migration toward CXCL12, CX3CL1 and CCL27 using a standard 
Transwell migration assay.  We found that apoptotic cells exposure did stimulate 
macrophage migration toward CXCL12 (Fig.5.3A).  However, we did not observe an 
impact on CX3CL1 and CCL27 driven chemotaxis (Fig.5.3A).  This suggested that 
efferocytosis could stimulate macrophage CXCR4 expression, but not CX3CR1 or 
CCR10.  In order to confirm the effect of efferocytosis on macrophage CXCR4 
expression, flow cytometry analysis was performed on macrophages that have been 
exposed to apoptotic cells.  Flow cytometry analysis confirmed that macrophage CXCR4 
expression was indeed upregulated in response to efferocytosis (Fig.5.3B).  This finding 
indicates that both Sdc-1 and CXCR4 expression can be upregulated in response to 
efferocytosis.  To determine the correlation between macrophage CXCR4 expression and 
Sdc-1 expression, macrophages that have been exposed to apoptotic cells were separated 
into two populations based on their CXCR4 expression level: low (CXCR4
lo




) expression level (Fig.5.4A).  Flow cytometry was then utilized to further 
characterize the Sdc-1 expression of these populations.  As expected, high CXCR4 








Figure 5.3.  Efferocytosis induces macrophage CXCR4 expression.  A.   Macrophage 
chemotaxis toward CXCL12, a ligand of CXCR4, can be induced following exposure to 
apoptotic cells.  Macrophage chemotaxis response was analyzed using transwell 
migration assay.  Macrophages were placed in the upper chamber of a transwell while 
select ligands were placed in the lower chamber (CXCL12, 200ng/mL; CX3CL1, 
400ng/mL; CCL27, 250ng/mL).  Apoptotic macrophages were also added to the upper 
chamber of the experimental group.  Macrophages that have migrated to the lower 
surface of the chamber were stained using hematoxylin, counted and reported as 
migration index (n=4).  **P<0.01.  B.  Macrophage CXCR4 expression can be induced 
following exposure to apoptotic cells.  Surface expression of CXCR4 was analyzed on 
macrophages that have been exposed to apoptotic cells using flow cytometry and 
quantified as MFI (filled: control, black line: experimental; n=4).  **P<0.01.  All data 
represent the mean ± SEM. 
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Figure 5.4.  High CXCR4 expression level in response to efferocytosis is associated with 
high Sdc-1 expression.  A.   Macrophages that have been exposed to apoptotic cells were 
separated into two population based on their CXCR4 expression level: low expression 
level (CXCR4
lo
) and high expression level (CXCR4
hi





 macrophage population using flow cytometry and 
quantified as MFI (filled: CXCR4
lo
, black line: CXCR4
hi
; n=4). **P<0.01.  All data 
represent the mean ± SEM. 
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5.2.3 Involvement of CXCR4 in mouse peritonitis model  
Macrophage efferocytosis and clearance out of the inflamed tissue are hallmark of 
tissue undergoing inflammation resolution.  However, the chemokine receptors that are 
potentially involved in macrophage clearance out of the inflamed tissue are still 
unknown.  Given our finding that macrophage CXCR4 expression was upregulated 
following macrophage exposure to apoptotic cells, we elected to investigate the potential 
involvement of CXCR4 in macrophage motility during inflammation using a murine 
model of peritonitis, an acute inflammatory model that has been widely utilized to study 
leukocyte recruitment and motility during inflammation.  Early during peritonitis, 
neutrophils are recruited into the peritoneal cavity where they subsequently turn apoptotic 
and are cleared by the macrophages through efferocytosis.  Thus, macrophages were 
collected early during the peritonitis response and analyzed using flow cytometry to 
check for their CXCR4 expression.  Of note, macrophages collected from mice not 
undergoing peritonitis were also collected for analysis, and no inherent CXCR4 
expression was observed (Fig.5.5A).  Significantly, we observed an upregulation in 
macrophage CXCR4 expression at 18 hours post peritonitis induction, indicating that 
CXCR4 was potentially involved in the regulation of macrophage migration during 
inflammation (Fig 5.5A).  To determine if CXCR4 was actively involved in macrophage 
migration during peritonitis, the effect of CXCR4 blockade was analyzed using 
AMD3100.  AMD3100, also known as Plerixafor, is a compound that works as an 
antagonist to CXCR4 [228-230].  While the inhibitory effect of AMD3100 on CXCR4 
mediated chemotaxis on hematopoietic stem cells and tumor cells has been well studied 
[228-230], the effect of AMD3100 on CXCR4 mediated macrophage chemotaxis has not 
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been previously characterized.  Thus, the ability of AMD3100 to block macrophage 
migration toward CXCL12 was first analyzed using a standard Transwell migration 
assay, where it was found to effectively limit macrophage chemotaxis toward CXCL12 
(Fig.5.5B).  To determine CXCR4 involvement in vivo, mice undergoing peritonitis were 
injected with AMD3100 or PBS at18 hours post peritonitis injection.  Flow cytometry 
analysis performed on peritoneal exudates obtained 6 hours post injection showed that 
macrophage count was increased in mice that were injected with AMD3100 compared to 
mice that received PBS injection (Fig.5.5C).  This result indicates that CXCR4 is 
involved in regulating macrophage migration during inflammation in peritonitis model 















Figure 5.5.  Macrophage CXCR4 is involved in the regulation of macrophage migration 
during peritonitis.  A. Macrophages were obtained 18 hours post peritonitis induction and 
CXCR4 expression was analyzed using flow cytometry and quantified as MFI (filled: 
control, black line: experimental; n=3).  *P< 0.05.  B. Effect of AMD3100 on 
macrophage chemotaxis toward CXCL12 was investigated by adding AMD3100 to the 
upper well in the experimental group (25µg/mL); no treatment was added to the control 
group.  After 18 hours, macrophages that migrated to the lower surface of the membrane 
were stained, counted and reported as migration index (n=3).  **P<0.01.  C. Effect of 
AMD3100 on macrophages during peritonitis response was investigated by AMD3100 
injection (125 µg/mouse) at 18 hr post induction.  Following 6 hours incubation period, 
peritoneal macrophages were obtained, stained and counted (n=6-8).  **P<0.01. All data 
represent the mean ± SEM. 
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5.2.4 CXCR4 involvement in macrophage egress to the lymphatics 
 Macrophage accumulation in chronic inflammation is thought to be the result of 
macrophage egress failure during inflammatory response. Previous studies have indicated 
that macrophage clearance during inflammation resolution involved macrophages egress 
to the surrounding draining lymph nodes [3, 41, 51, 128, 231].  Our observation that 
AMD3100 treatment resulted in macrophage accumulation within the peritoneal cavity 
suggested the involvement of CXCR4 in macrophage egress out of the inflammatory site 
to the draining lymph nodes.  To test this hypothesis, we utilized an adoptive transfer 
model in which fluorescently labeled macrophages were transferred into the peritoneal 
cavity of mice undergoing the same stage of peritonitis.  In order to verify CXCR4 
involvement in macrophage clearance to the draining lymph nodes, macrophages were 
first treated with AMD3100 prior to the adoptive transfer process and compared to 
untreated control macrophages.  10 hours of post-adoptive transfer, the number of 
fluorescently labeled macrophages in the peritoneal cavity was reduced in both 
experimental and control group.  However, a significantly greater amount of labeled 
macrophages were found in the peritoneal cavity of mice that were treated with 
AMD3100 (Fig.5.6A).  This result suggests that macrophage accumulation in the 
peritoneal cavity following AMD3100 administration was the result of macrophage 
failure to egress from the inflammation site.  In order to track the migration of the 
fluorescently labeled macrophages, mesenteric lymph nodes were harvested from both 
control and experimental groups.  Fluorescently labeled population recovered from the 
lymph nodes and spleen was analyzed using flow cytometry analysis and counted using 
counting beads.  As expected, the numbers of labeled macrophages that was recovered 
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from the mesenteric lymph nodes was significantly lower in mice that were treated with 
AMD3100 compared to the control group(Fig.5.6B).  Given our previous finding of 
macrophage retention in the peritoneal cavity following AMD3100 treatment, the 
observation of reduced labeled macrophages in the draining lymph nodes was not 
surprising.  Overall, these results suggest that CXCR4 is important in regulating 
macrophage egress from the inflammation site to the draining lymphatics and is 
















Figure 5.6.  CXCR4 blockade by AMD3100 resulted in  delayed macrophage clearance 
to the lymphatics.  Fluorescently labeled were adoptively transferred into the peritoneal 
cavity of WT mice undergoing the same stage of peritonitis.  Mice were sacrificed at 10 
hours post adoptive transfer and the peritoneal lavage and mesenteric lymph nodes were 
harvested and processed. A. Peritoneal lavage was analyzed for fluorescently labeled 
macrophages that remained in the peritoneal cavity (n=6).  *P<0.05.  B. Cell suspension 
obtained from the lymph node were analyzed to determine the presence of fluorescently 
labeled macrophages (n=10-11).  *P<0.05.   All data represent the mean ± SEM. 
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5.2.5 CXCR4 is expressed on human macrophages under M2 polarization. 
Thus far our results suggest that CXCR4 is a chemokine receptor that is expressed 
on M2 macrophages and is also potentially involved in macrophage egress during 
resolution.  To provide further insight into the regulation of CXCR4 expression on 
polarized macrophages, flow cytometry was used to analyze chemokine receptor 
expression on polarized human macrophages.  Human macrophages were obtained from 
circulating blood monocytes that were cultured in the presence of macrophage colony 
stimulating factor (M-CSF).  M1 polarization was achieved using IFN-γ and LPS 
treatment, while M2 polarization was achieved using adenosine treatment.  Surface 
expression of HLA-DR and CD163, known markers for M1 and M2 polarization 
respectively, and CXCR4 was analyzed. As expected, flow cytometry analysis of 
polarized human macrophages demonstrated significantly higher level of HLA-DR 
expression on M1 macrophages compared to M2 macrophages (Fig.5.7A).  On the 
contrary, M1 macrophages were found to display significantly lower level of CD163 
compared to M2 macrophages (Fig.5.7A).  Significantly, we observed that CXCR4 
expression, while nonexistent in M1 macrophages, was drastically upregulated on M2 
macrophages (Fig.5.7A).  Similar to murine macrophages, we found that exposure of 
macrophages to apoptotic cells resulted in the upregulation of CXCR4 expression 
(Fig.5.7B).  Thus, in line with our finding in murine system, CXCR4 is also associated 






Figure 5.7.  Sdc-1 expression is associated with M2 polarization state and CXCR4 
expression on human macrophages.  A. The expression of HLA-DR and Sdc-1 was 
analyzed on human macrophages following exposure to M1 stimulus (IFN-γ, 20ng/mL + 
LPS, 100ng/mL), or 6-benz-cAMP (100µM), (n=3-4).  **P<0.01.  B.  Macrophage 
CXCR4 expression following efferocytosis was analyzed using flow cytometry and 
quantified as MFI (n=3).  *P<0.05.  All data represent the mean ± SEM. 
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5.3 Discussion 
Macrophage accumulation within the inflammation site is one of the defining 
features of many chronic inflammatory disease, including rheumatoid arthritis, chronic 
liver disease, chronic kidney disease and atherosclerosis [2, 121, 126, 154, 232].  While 
previous efforts have been focused on understanding monocyte recruitment into the 
inflammation site and their roles in the orchestration of inflammatory response, recent 
findings have suggested that both efferocytosis and macrophage egress can also have a 
profound effect on the outcome of inflammation.  In fact, efferocytosis has often been 
suggested to dampen macrophage activation state and trigger macrophage egress from the 
inflammation site into the draining lymph nodes [50, 99, 103, 171].  Despite these 
assertions, the link between macrophage efferocytosis and macrophage motility is not 
actually well understood.  In this project, our investigation have identified CXCR4 as an 
endogenous receptor that was expressed on M2 polarized macrophages.  Notably, 
macrophage CXCR4 expression was found to coincide with Sdc-1 expression, which we 
have demonstrated to associate with M2 polarization.  Moreover, we provide evidence 
that macrophage CXCR4 expression can be triggered by efferocytosis.  Significantly, 
CXCR4 was also found to participate in macrophage egress from inflammation site to the 
draining lymph nodes.  Thus, macrophage expressed CXCR4 is potentially a part of the 
mechanism by which efferocytosis results in macrophage egress from the inflammation 
site, leading to the resolution of inflammatory response.  
Macrophage involvement during the course of inflammatory response is well 
established.  The concept of macrophage polarization states, inflammatory mediator 
secretion and efferocytosis and how they may affect inflammation have been described in 
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numerous independent studies [10, 13, 99, 103, 124, 140, 171, 202].  Although 
macrophage is known to orchestrate inflammatory response, the notion that macrophage 
motility can have a major impact on inflammatory outcome has not been widely 
considered before.  However, several reports have demonstrated that macrophage motility 
can potentially play a crucial role in determining the outcome of inflammatory response 
[29, 203].  A study done by van Gils et al has demonstrated that blockade of macrophage 
migration could result in macrophage accumulation within the vascular wall, which 
resulted in the pathogenic progression of atherosclerosis [203].  Conversely, stimulating 
macrophage migration within the plaque was associated with increased macrophage 
clearance and plaque regression.  Enhanced macrophage motility has also been linked 
with the anti-inflammatory cAMP signaling and M2 polarization state [29].  
Unfortunately, characterization of both macrophage polarization states and specific 
chemokine receptors expressions were not performed in those studies.  On the contrary, 
our findings have clearly demonstrated that M1 and M2 macrophages differ in their 
chemokine receptor expression.  In particular, CXCR4, CX3CR1 and CCR10 were found 
to be significantly upregulated in M2/Sdc-1
+
 compared to M1 macrophages.  In 
agreement with previous reports, CCR7 was found to be upregulated in M1 compared to 
M2/Sdc-1
+
 macrophages [129, 200].  Not surprisingly, the unique chemokine receptor 
repertoire of polarized macrophages resulted in distinct chemotaxis behavior; M1 
polarization significantly inhibited, while M2 polarization promoted macrophage 
chemotaxis toward CXCL12, CX3CL1 and CCL27.  Thus, macrophage motility is 
emerging as an important mechanism through which macrophages orchestrate the 
inflammatory response. 
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Although macrophage exposure to adenosine can result in the expression of 
CXCR4, CX3CR1 and CCR10 on M2/Sdc-1
+
 polarized macrophages, the biophysical 
process  by which their expression can be regulated in vivo is unknown.  Efferocytosis is 
a process that has long been recognized to be necessary in the resolution of inflammation.  
In addition to ensuring the prompt removal of cellular debris and apoptotic cells out of 
the inflamed tissue, efferocytosis has also been suggested to promote resolution by 
promoting macrophage egress [49, 99].  A recent study by Driscoll at al has also 
demonstrated that enhanced macrophage efferocytosis could accelerate macrophage 
clearance from the peritoneum in a murine peritonitis model, thus promoting 
inflammation resolution  [49].  In addition, efferocytosis has been reported to result in the 
release of adenosine during inflammation [219].  Given the link between efferocytosis, 
enhanced motility and adenosine release, efferocytosis appears to be a likely candidate 
for triggering CXCR4, CX3CR1 and CCR10 expression in vivo.  Unexpectedly, we did 
not observe a significant impact on macrophage chemotaxis toward CX3CL1 and CCL27 
following exposure to apoptotic cells.  However, macrophage chemotaxis response 
toward CXCL12 was found to be significantly upregulated following efferocytosis, 
indicating an upregulation of CXCR4 expression, which was confirmed through flow 
cytometry analysis.  Significantly, high macrophage CXCR4 expression level was 
associated with high Sdc-1 expression level.  Overall, our finding indicates that Sdc-1 
and CXCR4 can be expressed on macrophages under similar physiologic condition 
during inflammation response.   
CXCR4 involvement in the regulation of macrophage motility in vivo was 
analyzed using peritonitis, a commonly utilized acute inflammatory model for studying 
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leukocyte recruitment and migration.  Neutrophils, which are recruited early during 
peritonitis response, can quickly turn apoptotic following their extravasation and are 
subsequently cleared through efferocytosis.  We demonstrated that macrophages that 
were obtained during this time frame expressed CXCR4 on their surface.  Notably, we 
observed no evidence of CXCR4 expression on macrophages obtained from mice not 
undergoing peritonitis.  CXCR4 involvement in the regulation of macrophage migration 
during inflammation was verified using AMD3100, a CXCR4 antagonist that blocks 
macrophage chemotaxis toward CXCL12 in vitro.  Consistent with our hypothesis, 
CXCR4 blockade via AMD3100 treatment resulted in macrophage accumulation within 
the peritoneal cavity, which was presumably caused by reduced macrophage emigration.  
Overall, our results suggest that although M2 macrophages express CXCR4, CX3CR1 
and CCR10, only CXCR4 expression is regulated through efferocytosis during 
inflammation.  In addition, CXCR4 expression is potentially a part of the mechanism 
activated by efferocytosis that is designed to support macrophage egress from the 
inflammation site. 
Macrophage accumulation during chronic inflammation can be partly explained 
by reduced macrophage clearance out of the inflammatory site.  While the fate of 
emigrating macrophages is not fully known, macrophage presence in the draining 
lymphatics during resolution has been documented previously [99, 128, 198, 199].  Given 
the therapeutic potential of stimulating macrophage egress, uncovering mechanisms that 
regulate macrophage clearance toward the draining lymph nodes has been the subject of 
various reports [49, 99, 128, 198, 199].  Schiff-Zuck et al reported that enhanced 
efferocytosis was associated with macrophage clearance toward the lymph nodes during 
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the resolution of murine peritonitis [99].  Cao et al has also demonstrated the importance 
of macrophage integrin Mac-1 in accelerated macrophage efflux from the peritoneal 
cavity to the lymphatics in response to LPS stimulation during peritonitis [128].  
Consistent with these reports, we found that macrophage clearance from the inflamed 
peritoneal cavity involved macrophage migration toward the lymphatics.  Utilizing an 
adoptive transfer model of fluorescently labeled macrophages, we demonstrated the 
involvement of CXCR4 in macrophage egress toward lymph nodes.  Significantly, 
CXCR4 blockade resulted in the accumulation of fluorescently labeled macrophages in 
the peritoneal cavity, which was coupled with reduced clearance to the draining lymph 
nodes.  These results suggest that CXCR4 is one of the chemokine receptors that is 
involved in driving macrophage egress during inflammation resolution.  To our 
knowledge, this is the first report in which macrophage expressed CXCR4 has been 
demonstrated to actively participate in macrophage egress toward the lymphatics during 
inflammatory resolution.   
5.4 Conclusion 
Several reports have established the importance of macrophage egress on the 
resolution of inflammatory response.  We therein demonstrate that polarized 
macrophages express a unique chemokine receptor repertoire and chemotaxis response.  
While CXCR4, CX3CR1 and CCR10 were all upregulated on adenosine induced 
macrophages, only CXCR4 expression was regulated through macrophage efferocytosis.  
Notably, macrophage CXCR4 was found to participate in macrophage egress from the 
inflammation site toward the draining lymphatics.  Thus, CXCR4 expression on 
macrophages may play an important role not only in regulating macrophage migration 
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response during inflammation but also in potentially influencing the outcome of many 




5.5.1 Macrophage Culture and Activation 
C57BL6 wild type (WT) mice were purchased from Jackson Laboratory.  
Syndecan-1 (Sdc-1)
-/-
 mice (back crossed 10 times onto a C57BL6 background) was 
kindly provided by Dr. Pyong Woo Park, (Baylor College of Medicine, Houston, TX).  
All procedures were performed in male mice according to a protocol approved by Emory 
University and Beth Israel Deaconess Medical Center Institutional Animal Care and Use 
Committee.  
Murine peritonitis was induced by the IP injection of 0.5mL of 6% sterile TG 
broth, which was prepared from dehydrated TG medium (Sigma Aldrich) and sterile 
water.  Peritoneal macrophages were obtained through lavage using 5mL of sterile PBS 
with 1mM EDTA  at 4 or 5 days following peritonitis initiation, unless otherwise noted.  
Peritoneal macrophages were cultured in DMEM (Cellgro) containing 10% FBS 
(Cellgro), 100U/mL penicillin and 100µg/ml streptomycin sulfate (Sigma Aldrich) at 
37°C in 5% CO2 humidified incubator.  Where indicated, macrophage M1 activation was 
induced by culturing macrophages overnight in the presence of  Ifn-γ (100U/mL) and 
LPS (100ng/mL).  Sdc-1 expression was induced by culturing macrophage overnight with 
Adenosine (Sigma Aldrich, 375 µM).   
Human acute monocytic leukemia cell line was obtained from ATCC and cultured 
as previously described (Chapter 3, Method Section).  Monocytic differentiation was 
induced by incubation of 1x10
7
 cells in 100x200mm tissue culture dish in culture media 
that has been supplemented with 50ng/mL of phorbol 12-myrisate 13-acetate (PMA) 
(Sigma Aldrich) for 3 days.  After the differentiation period, M1 polarization was 
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induced by culturing macrophages overnight with Ifn-γ (20ng/mL) and LPS (100ng/mL), 
while M2 polariztion was induced by culturing macrophage overnight with Ado 
(375µM).  
5.5.2 PCR Array 
mRNA expression analysis of 84 genes that encode chemokines and their 
receptors were performed using mouse chemokines and receptors RT2 profiler PCR array 
(SABiosciences).  RNA was extracted from classically activated M1 and Sdc-1
+
 
(Adenosine) macrophages with TRIzol reagent (Invitrogen) and purified using RNeasy 
mini kit (Qiagen) according to manufacturer’s protocol.  A total of 1µg of RNA from 
each sample were converted to cDNA using the RT
2
 first strand kits (SABiosciences) and 
was then subjected to PCR array analysis on the Applied Biosystems 7900 using the RT
2
 
qPCR Master Mixes according to manufacturer’s protocol (SABiosciences).  Data were 
analyzed using the web-base PCR array data analysis tool from SABiosciences.  mRNA 
expression level for each gene was normalized to  the expression level of 
glyceraldehydes-3-phosphage dehydrogenase (GAPDH) using the equation 2
-(Ct[gene of 
interest]-Ct[GAPDH])
, where Ct is the threshold cycle.  Normalized gene expression levels of 
experimental samples (Sdc-1
+
 macrophages) were obtained by comparing the gene 
expression level to control samples (M1 macrophages). Each reported value represents 
the mean fold increase or fold decrease of mRNA expression in experimental samples 
relative to controls.   
5.5.3 Flow cytometry 
Isolated macrophages for surface marker expression analysis were passed through 
a 70-micron cell strainer to remove debris and then counted and resuspended in FACS 
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buffer (1%  BSA in PBS) at a concentration of 5x10
6
/mL.  Staining was performed by 
combining the manufacturer’s recommended quantity of primary antibody to 100µL of 
cell suspension, followed by 30 minutes of incubation at 4°C.  Cells were washed twice 
before being analyzed on the flow cytometer (LSRII, Becton Dickinson).  
The cell antibodies used mouse cell staining included: anti-F4/80 (BM8), anti-
CD138/Sdc-1 (281-2) and anti-CD184/CXCR4 (2B11); negative controls with isotype 
IgG were included for each marker.  Anti-F4/80 antibody was obtained from eBioscience 
and the rest were obtained from BD Biosciences.  
The cell antibodies used for human cell surface markers analysis included: anti-
HLA-DR (G46-6), anti-CD163 (GHI/61), and anti-CD184/CXCR4 (12G5); negative 
controls with isotype IgG were included for each marker.  All of the antibodies were 
obtained from BD Biosciences.  
5.5.4 Generation of Apoptotic Macrophages and Efferocytosis Experiment 
Apoptotic peritoneal macrophages and RAW 264.7 macrophages were generated 
as described previously (Chapter 3, Method Section).  Apoptotic THP1 macrophages 
were generated similarly by exposure of plated macrophages to UV light.  However, 
macrophages were exposed to UV light for 10 minutes and were additionally cultured for 
2.5 hours 
To investigate murine macrophage CXCR4 expressing following efferocytosis, 
apoptotic RAW 264.7 cells were added to peritoneal macrophages (15 to 1 ratio)  
cultured  in DMDM supplemented with 0.5% FBS, which were then placed at 37°C in 
5% CO2 humidified incubator.  Following 2 hours of incubation, excess apoptotic cells 
were removed by washing with PBS and remaining macrophages were cultured for 
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additional 40 hours.  Macrophages were removed using harvested using non-enzymatic 
cell dissociation buffer (Sigma Aldrich) and washed using PBS prior to being stained for 
flow cytometry analysis.  
To investigate human CXCR4 expression following efferocytosis, apoptotic 
THP1 cells were added to peritoneal macrophages (15 to 1 ratio) cultured  in RPMI 
supplemented with 0.5% FBS, which were then placed at 37°C in 5% CO2 humidified 
incubator.  Following 2 hours of incubation, excess apoptotic cells were removed by 
washing with PBS and remaining macrophages were cultured for additional 40 hours.  
Macrophages were removed using harvested using non-enzymatic cell dissociation buffer 
(Sigma Aldrich) and washed using PBS prior to being stained for flow cytometry 
analysis.  
5.5.5 Macrophage Chemotaxis 
Chemotaxis response of polarized macrophages was analyzed by loading 100 µL 




 mice that have been resuspended at a 
concentration of 1x10
6
/mL in DMEM containing 0.5% FBS, onto the upper well of a 24-
well transwell permeable supports with a pore size of 8µm (Corning); DMEM containing 
0.5% FBS was added onto the lower well.  During the 4-hour-incubation period, M1 
stimulus or Adenosine was added onto both upper and lower chambers.  After 4h, the 
media and stimulus was removed and fresh DMEM containing 0.5% FBS added onto 
both chambers.  The chemokines CXCL12 (200ng/mL), CX3CL1 (400ng/mL) or CCL27 
(250ng/mL) was added onto the lower chambers of experimental group, while no 
chemokines were added in the control groups.  After 18h of incubation, macrophages that 
have migrated onto the lower well surface of the membrane were fixed with 10% 
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formalin in PBS for 10 minutes.  Macrophages that adhere to the upper well were scraped 
and the membrane was then stained with hematoxylin.  For each replicate, 3 separate 
wells containing peritoneal macrophages obtained from separate mouse were included.  
The numbers of macrophages in three independent fields of view were counted in each 
well and averaged.  Migration was quantified as migration index by dividing the number 
of macrophages counted in experimental compared to control group.  
To investigate the chemotaxis response of macrophages that have been exposed to 
apoptotic cells, 100 µL of peritoneal macrophages that have been resuspended at a 
concentration of 1x10
6
/mL in DMEM containing 0.5% FBS were added onto the upper 
chamber of a transwell permeable support; 600µL of DMEM containing 0.5% FBS was 
also added onto the lower chamber.  Macrophages were allowed to adhere for 1 h before 
5x10
5
apoptotic peritoneal macrophages in 50µL of media was added onto the upper well 
of experimental group; 50µL of media was added onto the upper well of control group.  
After 4 hours of incubation, the base media was removed from the lower chamber, and 
media containing the chemokines CXCL12 (200ng/mL), CX3CL1 (400ng/mL) or CCL27 
(250ng/mL) was added onto the lower chambers of both experimental and control group. 
After 18 hours, migration response was analyzed as described above. 
5.5.6 CXCR4 blocking – AMD3100 
 In order to investigate effect of AMD3100 on macrophage chemotaxis toward 
CXCL12 in vitro, chemotaxis experiment was set up as described above using 
macrophages that have been treated with Ado.  AMD3100  (Sigma Aldrich) was added 
onto the upper well of the experimental group (25µg/mL); no treatment was added to the 
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control group.  After 18 hours, macrophages that migrated to the lower surface of the 
membrane were stained, counted and reported as migration index as described above.   
To investigate the effect of AMD3100 on macrophage migration in vivo, Mice 
were IP injected with 0.5 mL of 6% sterile TG broth to induce peritonitis.  AMD3100 
(200µL of 625µg/mL solution in PBS) was then IP injected at 18 hours post TG injection 
,while equal volume of sterile PBS was injected in the control group.  Mice were 
sacrificed after 6 hours, and peritoneal lavage was performed using 5mL of sterile PBS 
with 1mM EDTA.  The number of macrophages in the peritoneal lavage was determined 
by performing total cell count and analyzing the percentages of macrophages using flow 
cytometry analysis with mouse F4/80 antibody staining.  
5.5.7 Adoptive transfer 
For adoptive cell transfer experiments, peritonitis was induced in both donor and 
recipient mice.  Macrophages were obtained through lavage at 18 hours post peritonitis 
induction and labeled with 3µM CellTace Violet (Invitrogen) according to 
manufacturer’s suggestion.  Labeled macrophages were then counted and resuspended in 
sterile PBS.  In the experimental group, AMD3100 was then added at a concentration of 
25µg/mL and was incubated at 4°C in the dark for 30 minutes; no treatment was added 
onto the control group.  Cell suspension was then injected into the peritoneal cavity of 
recipient mice undergoing the same stage of peritonitis (18 hours post peritonitis 
induction).  Recipient mice also received AMD3100 injection intraperitoneally in the 
experimental group (200µL of 625µg/mL solution in PBS), while equal volume of sterile 
PBS was injected in the control group.  Recipient mice were then sacrificed 10 hours post 
adoptive transfer and the mesenteric lymph nodes were harvested and processed for flow 
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cytometry analysis, as described previously (Chapter 3, Method Section).  Relative cell 
number was obtained by dividing the number of recovered cells with the average of the 
recovered cells from control mice.   
5.5.8 Statistical Analysis 
Means and SEM were calculated for each parameter.  All data were analyzed via 
2-tailed Student t test.  For the PCR array analysis, the P values were calculated based on 
a Student t test of the replicate 2
-(Ct[gene of interest]-Ct[GAPDH]) 
values for each gene in both the 
control and experimental groups.  Values of P<0.05 were considered statistically 





 This last decade has witnessed a profound leap in our understanding of 
inflammation resolution.  Once regarded as a passive process, resolution is now 
understood to be an active process that is regulated by numerous complex mechanisms 
that work together to ensure the return of tissue homeostasis.  Ongoing research has 
discovered numerous chemical mediators, signaling pathways and biophysical processes 
that are essential in the resolution of inflammation.  Despite the significant progress that 
has been made, many of the mechanisms involved in inflammation resolution are still 
poorly understood.   Given the prevalence of chronic inflammatory diseases and the lack 
of effective therapeutics, developing a deeper understanding of the mechanisms involved 
in the resolution of inflammation can help lead to novel treatment approaches.  
 In this dissertation, we uncovered a unique population of macrophages expressing 
Sdc-1 that are present within the vascular wall of mice undergoing atherosclerosis.  
Consistent with previous publications by our group and others that report the protective 
effect of Sdc-1 expression in various inflammation models, the presence of Sdc-1 
expressing macrophage was found to limit atherosclerosis progression.  In addition, 
macrophage Sdc-1 expression was associated with anti-inflammatory M2 polarization 
state, efferocytosis, high intrinsic motility and macrophage egress from the inflammation 
site to the lymphatic network, all of which are considered essential for the successful 
resolution of inflammation.  
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 In the first phase of this study, we attempted to characterize the polarization state 
of macrophages that are expressing Sdc-1 in vitro and within atherosclerotic plaque.  We 
investigated the expression of several surface markers that are known to be expressed on 
M1 and M2a macrophages. We also tested the iNOS activity, arginase activity, IL-10 
production, phagocytosis, intrinsic motility and adhesion characteristic of Sdc-1 
expressing macrophages against standard polarized M1, M2a and M2c macrophage 
populations.  Sdc-1
-/- 
macrophages were also utilized in select studies to confirm Sdc-1 
involvement in the regulation of macrophage functions.  These characterization efforts 
established the anti-inflammatory nature of Sdc-1 expressing macrophages, in 
conjunction with increased macrophage migration response.  Importantly, efferocytosis 
was found to be a possible regulator of macrophage Sdc-1 expression.  The correlation 
that we discovered between efferocytosis, Sdc-1 expression and enhanced motility 
provided motivation to investigate the effect of macrophage Sdc-1 expression on 
macrophage motility in vivo.  
Based on the results obtained from our in vitro characterization of Sdc-1 
expressing macrophages, we hypothesized that the absence of Sdc-1 expression on 
macrophages can result in delayed macrophage clearance from the inflammation site to 
the draining lymphatics network.  Macrophage egress to the lymphatics is understood to 





 mice and a TG induced peritonitis model supported our hypothesis.  While the 
neutrophil response was found to be similar between the two groups, the absence of Sdc-
1 was found to result in the accumulation of macrophages in the peritoneal cavity, which 
is associated with delayed macrophage clearance.  In addition, we confirmed that the 
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delayed macrophage clearance was associated with dampened macrophage egress toward 
the draining lymph nodes.   Significantly, these findings demonstrated a direct 
involvement of Sdc-1 in macrophage egress during inflammatory responses, which 
supports the notion that Sdc-1 expression is a part of the mechanisms that regulate the 
resolution of inflammatory response. 
 Lastly, we attempted to identify specific chemokine receptors involved in 
macrophage egress during the resolution of inflammation.  We identified 3 chemokine 
receptors that were upregulated in Sdc-1 expressing M2 polarized macrophages, 
CX3CR1, CXCR4 and CCR10.  However, only CXCR4 was found to be expressed and 
functionally active following macrophage exposure to apoptotic cells.  Similar to 
macrophage Sdc-1 expression, we were able to confirm that efferocytosis can also result 
in the upregulation of macrophage CXCR4 expression.  In fact, macrophages expressing 
high level of CXCR4 were found to also express high level Sdc-1 expression on their 
surface.  This observation suggests that Sdc-1 and CXCR4 are expressed on macrophage 
surface under similar physiological stimulus.  Further tests utilizing AMD3100, a 
CXCR4 blocker, in murine peritonitis model confirmed that macrophage CXCR4 is 
involved in the regulation of macrophage clearane.  CXCR4 blockade resulted in the 
accumulation of macrophages within the peritoneal cavity which was associated with 
delayed macrophage egress toward the draining lymph nodes.  This agrees with our 
previous finding, which linked the absence of Sdc-1 expression with delayed macrophage 
egress during peritonitis.  Overall, we were able to demonstrate that macrophage Sdc-1 
expression is associated with CXCR4 expression, and are both important in ensuring 
macrophage clearance during inflammatory resolution.  
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 In summary, we demonstrate that Sdc-1 expression on macrophages is associated 
with an anti-inflammatory, pro resolution polarization state and enhanced migration.  
Macrophage Sdc-1 expression was also found to be correlated with CXCR4 expression, 
both of which can be upregulated in response to efferocytosis.  Importantly, both 
macrophage Sdc-1 and CXCR4 was found to participate in the regulation of macrophage 
egress from the inflammation site to the draining lymphatics during the resolution of 
inflammatory response.  While the overall mechanisms regulating resolution processes 
are unknown, our work has managed to identify two components that are involved in the 
process: macrophage Sdc-1 and CXCR4.  Collectively, these results reinforce the 
physiological significance of macrophage efferocytosis and macrophage motility as 
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